

## Krešimir Pavelić: popis znanstvenih publikacija

1. PAVELIĆ K., PAVELIĆ Z., HRŠAK I., Cytokinetic and morphological changes in lymphoid organs of mice with Ehrlich tumour. **Iugoslav. Physiol. Pharmacol. Acta**, 9: 407-415, 1973.
2. PAVELIĆ Z., BORANIĆ M., PAVELIĆ K., VAŠAREVIĆ M., Pathogenesis of ascites in a murine transplantable reticulosarcoma type A. **Z. Krebsforsch.**, 88: 91-95, 1976. **Q2**
3. PAVELIĆ Z., BORANIĆ M., BUNAREVIĆ A., PAVELIĆ K., DOMINIS M., VAŠAREVIĆ B., Studies on a transplantable reticulosarcoma type A of the mouse. **Period. biol.**, 79: 11-23, 1977. **Q3**
4. HRŠAK I., PAVELIĆ K., Effects of immunosuppression or immunostimulation on the growth rate of a lymphoid and of a myeloid leukemia in mice. **Cancer Immunol. Immunother.**, 3: 43-48, 1977. **Q1**
5. PAVELIĆ K., SLIJEPEČEVIĆ M., Growth of a thymoma in diabetic mice treated with insulin. **Europ. J. Cancer**, 14: 675-679, 1978. **Q1**
6. PAVELIĆ Z., BORANIĆ M., PAVELIĆ K., Morphology of lymphoreticular tissues in mice with reticulosarcoma. **Exp. Path.**, 15: 288-295, 1978.
7. PAVELIĆ K., HRŠAK I., Effects of immunosuppression on the growth of six murine tumors. **Z. Krebsforsch.**, 92: 147-156, 1978. **Q2**
8. PAVELIĆ K., SLIJEPEČEVIĆ M., PAVELIĆ J., Recovery of immune system in diabetic mice after treatment with insulin. **Horm. Metab. Res.**, 10: 381-386, 1978. **Q1**
9. PAVELIĆ K., Aplastic carcinoma in diabetic mice: Hyperglycemia-suppressed proliferation rate and insulin synthesis by tumor cells. **J. Nat. Cancer Inst.**, 62: 139-141, 1979. **Q1**
10. PAVELIĆ K., SLIJEPEČEVIĆ M., PAVELIĆ J., IVIĆ J., AUDY-JURKOVIĆ S., PAVELIĆ Z.P., BORANIĆ M., Growth and treatment of Erlich tumor in mice with alloxan-induced diabetes. **Cancer Res.**, 39: 1807-1813, 1979. **Q1**
11. HRŠAK I., TOMAŠIĆ J., PAVELIĆ K., VALINGER Z., Stimulation of humoral immunity by peptidoglycan monomer from Brevibacterium divaricatum. **Z. Immun. Forsch.**, 155: 312-318, 1979. **Q1**
12. PAVELIĆ K., PAVELIĆ Z., POLJAK-BLAŽI M., ŠVERKO V., The effect of insulin on the growth of transplanted tumors in mice. **Biomedicine**, 31: 125-127, 1979. **Q2**
13. HRŠAK I., TOMAŠIĆ J., PAVELIĆ K., BENKOVIĆ B., On the mechanism of immunostimulatory activity of monomeric peptidoglycans. **Period. biol.**, 81: 155-157, 1979. **Q3**
14. PAVELIĆ K., Induction of glucagon synthesis in diabetic CBA mice bearing mammary aplastic carcinomas. **J. Nat. Cancer Inst.**, 63: 1005-1008, 1979. **Q1**
15. PAVELIĆ K., PAVELIĆ J., BENKOVIĆ B., VUK-PAVLOVIĆ S., Correlation between hyperglycemia and reduced immune reactivity in mice. **IRCS Med. Sci.**, 8: 24, 1980.
16. PAVELIĆ J., PAVELIĆ K., Insulin stimulated phagocytic ability and humoral immunologic response in mice. **Horm. Metab. Res.**, 12: 42, 1980. **Q1**

17. PAVELIĆ K., Growth of a methylcholantrene-induced fibrosarcoma in mice with diabetes mellitus. **Europ. J. Cancer**, 16: 279-284, 1980. **Q1**
18. PAVELIĆ K., PAVELIĆ J., Glucagon suppressed proliferation rate of mammary aplastic carcinoma in mice. **Horm. Metabol. Res.**, 12: 243-246, 1980. **Q1**
19. PAVELIĆ J., BENKOVIĆ B., PAVELIĆ K., Growth and treatment of B-16 melanoma in hypoglycemic mice. **Res. Exp. Med.**, 177: 71-78, 1980. **Q1**
20. PAVELIĆ K., BAŠIĆ I., PAVELIĆ J., Habituation of a mammary aplastic carcinoma on diabetic conditions. **J. Cancer Res. Clin. Oncol.**, 97: 275-287, 1980. **Q2**
21. PAVELIĆ K., PEKIĆ B., SLIJEPEČEVIĆ M., POPOVIĆ M., Insulin levels in Hodkin's disease. **Brit. J. Haematol.**, 46: 133-135, 1980. **Q1**
22. PAVELIĆ K., HRŠAK I., Chemotherapy and immunotherapy of diabetic and non-diabetic mice bearing fibrosarcoma. **Europ. J. Cancer**, 16: 1297-1301, 1980. **Q1**
23. BENKOVIĆ B., PAVELIĆ J., PAVELIĆ K., The ability of melanoma B-16 cells to form colonies in the lungs of alloxan-diabetic mice. **Biomedicine**, 33: 135-136, 1980. **Q2**
24. PAVELIĆ K., VUK-PAVLOVIĆ S., Retarded growth of murine tumors in vivo by insulin- and glukagon-stimulated immunity and phagocytosis. **J. Nat. Cancer Inst.**, 66: 889-892, 1981. **Q1**
25. PAVELIĆ K., POPOVIĆ M., Insulin and glucagon secretion by renal adenocarcinoma. **Cancer (Philad.)**, 48: 98-100, 1981. **Q1**
26. PAVELIĆ K., GABRILOVAC J., BOŽIKOV V., PAVELIĆ J., PETEK M., BORANIĆ M., Somatostatin suppresses growth of murine myeloid leukemia. **Blood**, 57: 805-809, 1981. **Q1**
27. PAVELIĆ K., FERLE-VIDOVIĆ A., OSMAK M., VUK-PAVLOVIĆ S., Synthesis of immunoreactive insulin in vitro by aplastic mammary carcinoma preconditioned in diabetic mice. **J. Nat. Cancer Inst.**, 67: 687-688, 1981. **Q1**
28. PAVELIĆ K., PEKIĆ B., GABRILOVAC J., BRATIĆ-MIKEŠ V., BORANIĆ M., Hormonal changes in patients with haematological malignancies. **Biomedicine**, 35: 181-184, 1981. **Q2**
29. VUK-PAVLOVIĆ S., BOŽIKOV V., PAVELIĆ K., Somatostatin-reduced proliferation of murine aplastic carcinoma conditioned to diabetes. **Int. J. Cancer**, 29: 683-686, 1982. **Q1**
30. BORANIĆ M., GABRILOVAC J., PAVELIĆ J., FERLE-VIDOVIĆ A., PAVELIĆ K., ŠKARIĆ Đ., ŠKARIĆ V., Tetrapeptide H-Tyr-His-Lys-Lys-OH interferes with proliferation of normal and malignant cells in vitro. **Acta Pharm. Jugosl.**, 32: 105.-112, 1982.
31. GABRILOVAC J., PAVELIĆ J., MARUŠIĆ S., ORŠANIĆ L., SUCHANEK E., PAVELIĆ K., Anabolic hormone levels in immunized rats. **Immunology Letters**, 4: 345-347, 1982. **Q2**
32. PAVELIĆ K., BOLANČA M., VEČEK N., PAVELIĆ J., MAROTTI T., VUK-PAVLOVIĆ S., Carcinomas of the cervix and corpus uteri in humans: Stage-dependent blood levels of substance(s) immunologically cross-reactive with insulin. **J. Nat. Cancer Inst.**, 68: 891-894, 1982. **Q1**
33. PAVELIĆ K., RADIĆ S., PAVELIĆ J., Different endocrinological properties, growth rate and sensitivity to chemotherapy of aplastic mammary carcinoma in normo- and hypoglycemic phase of tumor growth. **Res. Exp. Med.**, 181: 63-76, 1982. **Q1**

34. PAVELIĆ K., ODAVIĆ M., PEKIĆ B., HRŠAK I., VUK-PAVLOVIĆ S., Correlation of substance(s) immunologically cross-reactive with insulin, glucose and growth hormone in Hodgkin lymphoma patients. **Cancer Letters**, 17: 81-86, 1982. **Q1**
35. VUK-PAVLOVIĆ S., PAVELIĆ K., Towards in vitro verification of a hormone mediated feed-back mechanism of tumor growth. **Period. biol.**, 84: 336-338, 1982. **Q3**
36. PAVELIĆ K., SIROTKOVIĆ M., KOPITAR M., PAVELIĆ J., VUK-PAVLOVIĆ S., Murine myeloid leukemia: in vivo suppression by serycystatin A, a proteinase inhibitor from leukocytes. **Europ. J. Cancer. Clin. Oncol.**, 19: 123-126, 1983. **Q2**
37. PAVELIĆ K., VUK-PAVLOVIĆ S., C-peptide does not parallel increases of substances immunologically cross-reactive with insulin in non-Hodgkin lymphoma patients. **Blood**, 61: 925-928, 1983. **Q1**
38. PAVELIĆ K., PETRUŠIĆ LJ., OSMAK M., ČULO F., In vitro and in vivo effect of progesterone on growth of some mouse and human tumors. **Res. Exp. Med.**, 183: 183-191, 1983. **Q1**
39. ŽUPANOVIĆ Ž., GABRILOVAC J., BRAYER D., ROČIĆ B., PAVELIĆ K., Insulin receptors on cells of mouse myeloid leukemia. **Period. Biol.**, 85: 97-98, 1983. **Q3**
40. PAVELIĆ LJ., PAVELIĆ K., VUK-PAVLOVIĆ S., Human mammary and bronchial carcinomas. In vivo and in vitro secretion of substances immunologically cross-reactive with insulin. **Cancer**, 53: 2467-2471, 1984. **Q1**
41. BAJZER Ž., PAVELIĆ K., VUK-PAVLOVIĆ S., Growth self-incitement in murine melanoma B-16, a phenomenological model. **Science**, 225: 930-932, 1984. **Q1**
42. MAROTTI T., SIROTKOVIĆ M., PAVELIĆ J., GABRILOVAC J., PAVELIĆ K., In vivo effect of progesterone and estrogen on tymus mass and T-cell functions in female mice. **Horm. Metab. Res.**, 16: 201-203, 1984. **Q1**
43. PAVELIĆ K., ZGRADIĆ I., OSMAK M., POPOVIĆ M., Estramustine phosphate-reduced proliferation of murine and human cell lines and murine transplantable tumors. **Res. Exp. Med.**, 185: 233-243, 1985. **Q1**
44. BALTIĆ V., LEVANAT S., PETEK M., BRATIĆ-MIKEŠ V., PAVELIĆ K., VUK-PAVLOVIĆ S., Elevated levels of substances immunologically cross-reactive with insulin in blood of patients with malignant pulmonary tissue proliferation. **Oncology**, 42: 174-178, 1985. **Q2**
45. PAVELIĆ K., L-ascorbic acid-induced DNA strand breaks and cross links in human neuroblastoma cells. **Brain Res.**, 342: 369-373, 1985. **Q1**
46. PAVELIĆ K., BEERMAN T.A., BERNACKI R.J., An evaluation of the effects of combination chemotherapy in vitro using DNA-reactive agents. **Cancer Drug Deliver.**, 2: 255-270, 1985.
47. PAVELIĆ K., PEKIĆ B., Elecrophoretic distribution and dissociation into subunits of lactate dehydrogenase derived from human myeloid leukemia cells before and after induction of differentiation. **J. Cell Physiol.**, 126: 307-311, 1986. **Q1**
48. PAVELIĆ K., VRBANEĆ D., MARUŠIĆ S., LEVANAT S., ČABRIJAN T., Autocrine tumor growth regulation by somatomedin C: an in vitro model. **J. Endocrinol.**, 109: 233-238, 1986. **Q1**
49. VUK-PAVLOVIĆ Z., PAVELIĆ K., VUK-PAVLOVIĆ S., Modulation of in vitro growth of murine myeloid leukemia by an autologous substance immunochemically cross-reactive with insulin and antiinsulin serum. **Blood**, 67: 1031-1035, 1986.

50. VUK-PAVLOVIĆ S., OPARA E.C., LEVANAT S., VRBANEĆ D., PAVELIĆ K., Autocrine tumor growth regulation and tumor-associated hypoglycemia in murine melanoma B16 in vivo. **Cancer Res.**, 46: 2208-2212, 1986. **Q1**
51. PAVELIĆ K., BULBUL M.A., SLOCUM H.K., PAVELIĆ Z.P., RUSTUM Y.M., NIEDBALA M.J., BERNACKI R.J., Growth of human urological tumors on extracellular matrix as a model for the in vitro cultivation of primary human tumor explants. **Cancer Res.**, 46: 3653-3662, 1986. **Q1**
52. BULBUL M.A., PAVELIĆ K., SLOCUM H.K., FRANKFURT O.S., RUSTUM Y.M., HUBEN R.P., BERNACKI R.J., Growth of human urologic tumors on extracellular matrix. **J. Urology**, 136: 512-516, 1986. **Q1**
53. PAVELIĆ K., Calmodulin antagonist W13 prevents DNA repair after bleomycin treatment of human urological tumor cells growing on extracellular matrix. **Int. J. Biochemistry**, 19: 1091-1095, 1987.
54. PAVELIĆ K., BERNACKI R.J., VUK-PAVLOVIĆ S., Insulin-modulated interleukin-2 production by murine splenocytes and T-cell hybridoma. **J. Endocrinology**, 114: 89-94, 1987. **Q1**
55. KOS Z., PAVELIĆ LJ., PEKIĆ B., PAVELIĆ K., Reversal of human myeloid leukemia cells into normal granulocytes and macrophages: activity and intracellular distribution of catalase. **Oncology**, 44: 245-247, 1987. **Q2**
56. PAVELIĆ K., SPAVENTI Š., Nerve growth factor (NGF) induced differentiation of human neuroblastoma cells. **Int. J. Biochemistry**, 19: 1237-1240, 1987.
57. ČABRIJAN T., PAČARIŽI H., LEVANAT S., VRBANEĆ D., PAVELIĆ J., MILKOVIĆ D., SPAVENTI R., KONČAR M., BALTIĆ V., SPAVENTI Š., PAVELIĆ K., Autocrine tumor growth regulation by the insulin growth factor I (IGF I) and the epidermal growth factor (EGF). **Progress in Cancer and Therapy**, Vol. 35, **Hormones and Cancer** 3, edited by F. Bresciani, R.J.B. King, M.E. Lippman and J.P. Raynaud. Raven Press, Ltd. New York, 227-230, 1988.
58. BERNACKI R.J., PAVELIĆ K., SULLIVAN C.L., LETO G., BULBUL M.A., RUSTUM Y.M., NIEDBALA M.J., CRICKARD K., Interactions of human carcinoma cells with extracellular matrix. **Tumor Progression and Metastasis**, edited by G.I.. Nicolson and I.J. Fidler. Alan R. Liss, Inc., New York, 251-260, 1988.
59. BERNACKI RJ, PAVELIĆ K., SULLIVAN C.L., LETO G., BULBUL M.A., RUSTUM Y.M., NIEDBALA M.J., CRICKARD K., Interactions of human carcinoma cells with extracellular matrix.In: **Tumor Progression and Metastasis**, (edited by Nicolson GL and Fidler IJ). Alan R. Liss, Inc., New York, 251-260, 1988.
60. OSMAK M., SIROTKOVIĆ M., LEVANAT S., KORBELIK M., PAVELIĆ K., Substance immunologically cross-reactive with insulin (SICRI) stimulates cell division. **Oncology**, 46: 54-57, 1989. **Q2**
61. LEVANAT S., PAVELIĆ K., Isolation and purification of a substance immunologically cross-reactive with insulin (SICRI) from human tissue. **Int. J. Biochemistry** 21: 509-515, 1989.
62. KRUSLIN B., LEVANAT S., BALTIĆ V., MILKOVIĆ D., PAVELIĆ J., SPAVENTI R., SPAVENTI Š., PAVELIĆ K., Growth factors in human tumors. **Res. Exp. Med.**, 189: 91-99, 1989. **Q1**
63. PAVELIĆ K., KOS Z., SPAVENTI Š., Antimetabolic activity of L-ascorbic acid in human and animal tumors. **Int. J. Biochemistry**, 21:931-935, 1989.
64. SPAVENTI R., ANTICA M., PAVELIĆ K., Insulin and insulin-like growth factor I (IGF I) in early mouse embryogenesis. **Development**, 108: 491-495, 1990. **Q1**

65. PAČARIZI H., SPAVENTI R., SPAVENTI Š., LEVANAT S., PAVELIĆ J., PAVELIĆ K., The expression of growth factors in human melanomas. **Tumordiagn.Ther.** 11: 37-40, 1990. **Q4**
66. LEVANAT S., PAVELIĆ K., Substance immunologically cross-reactive with insulin from murine myeloid leukemia: purification and characterization. **Biol. Chem. Hoppe-Seyler**, 371: 249-254, 1990.
67. PAVELIĆ K., BALTIĆ V., SPAVENTI Š., Artificial reversion of acute myeloid leukemia cells into hormonal phenotype. **Int. J. Biochemistry**, 22: 533-538, 1990.
68. MARUŠIĆ-GALEŠIĆ S., PAVELIĆ K., Dynamics of positive and negative selection in the thymus: review and hypothesis. **Immunology Letters**, 24:149-154, 1990. **Q2**
69. PAVELIĆ K., DESPOT N., LEVANAT S., ČASL T., Protective role of transforming growth factor beta (TGF b) in tumor-induced degradation of basement membranes. **Biol. Chem. Hoppe-Seyler**, 371:687-692, 1990.
70. OSMAK M., ECKERT-MAKSIĆ M., PAVELIĆ K., MAKSIĆ Z.B., SPAVENTI R, BEKETIĆ L, KOVAČEK I, ŠUŠKOVIĆ B., 6-Deoxy-6-bromo-ascorbic acid inhibits growth of mouse melanom cells. **Res. Exp. Med.** 190:443-449, 1990. **Q1**
71. PAVELIĆ K., PAVELIĆ Z.P., DENTON D., REISING J., KHALILY M., PREISLER H.D., Immunohistochemical detection of C-MYC oncprotein in paraffin embedded tissues. **J. Exp. Pathol.** 5: 143-153, 1990.
72. PAVELIĆ Z.P., PAVELIĆ LJ., PAVELIĆ K., PEACOCK J.S., Utility of anti-carcinoembryonic antigen monoclonal antibodies for differentiating ovarian adenocarcinomas from gastrointestinal metastasis to the ovary. **Gynecologic Oncology**, 40: 112-117, 1991. **Q1**
73. MARUŠIĆ-GALEŠIĆ S., PAVELIĆ K., POKRIĆ B., Cellular immune response to the antigen administered as an immune complex. **Immunology**, 72: 526-531, 1991. **Q1**
74. PAVELIĆ J., ZGRADIĆ I., PAVELIĆ K., Presence of estrogen receptors on target cells and antiproliferative activity of estramustine phosphate: positive correlation for human tumours in vitro. **J. Cancer. Res. Clin. Oncol.** 117: 244-248, 1991. **Q2**
75. ECKERT-MAKSIĆ M., KOVAČEK I., MAKSIĆ Z.B., OSMAK M., PAVELIĆ K., Effect of ascorbic acid and its derivatives on different tumors *in vivo* and *in vitro*. **Molecules in Natural Science and Medicine, An Encomium for Linus Pauling**, edited by Z.B. Maksić and M. Eckert-Maksić. Ellis Horwood, New York/London/Toronto/Sydney/Tokyo/Singapore, 509-524, 1991.
76. PAVELIĆ K., PAVELIĆ Z.P., PREISLER H.D., C-MYC detection in bone marrow biopsies. **Leukemia Res.** 15, 1075-1078,1991.
77. SLADE N., LEVANAT S., SPAVENTI Š., PAVELIĆ K., Collagenase derived from human fibrosarcoma is responsible for degradation of basement membranes. **Int. J. Exp. Pathol.** 72, 715-724,1991. **Q1**
78. ČABRIJAN T., LEVANAT S., PEKIĆ B., PAVELIĆ J., SPAVENTI R., FRAHM H., ZJAČIĆ-ROTKVIĆ V., GOLDONI V., VRBANEĆ D., MISJAK M., GRAZIO S., PAVELIĆ K., The role of insulin-related substance in Hodgkin's disease. **J. Cancer Res. Clin. Oncol.** 117, 615-619,1991. **Q2**
79. PAVELIĆ Z.P., PAVELIĆ LJ., PAVELIĆ K., GENTA R.M., RAY M.B., DVORNIK G., ŠČUKANEC-ŠPOLJAR M., PEACOCK J.S., Expression of carcinoembryonic antigen in

- ulcerative colitis, tubular adenomas and hyperplastic polyps: correlations with degree of dysplasia. **Anticancer Res.** 11, 1671-1676, 1991. **Q2**
80. PAVELIĆ K., PEĆINA N., SPAVENTI R., Growth factor and proto-oncogenes in early mouse embryogenesis. **Int. J. Dev. Biol.** 35: 209-214, 1991.
81. BANAVALI S.D., SILVESTRI F.F., PAVELIĆ K., PAVELIĆ Z.P., SMITH P.L., PREISLER H.D., Studies of the geographic patterns of c-myc expression in bone marrow. **Cell Prolif.** 24: 529-542, 1991. **Q3**
82. PAVELIĆ Z.P., PAVELIĆ LJ., PAVELIĆ K., DVORNIK G., ŠČUKANEĆ-ŠPOLJAR M., PEACOCK J.S., Immunohistochemical detection of carcinoembryonic antigen (CEA) with anti-CEA monoclonal antibodies in conventional tissue sections. **Period. biol.** 93: 479-484, 1991. **Q3**
83. PAVELIĆ Z.P., PAVELIĆ K., CARTER C.P., PAVELIĆ LJ., Heterogeneity of *c-myc* expression in histologically similar infiltrating ductal carcinomas of the breast. **J. Cancer Res. Clin. Oncol.** 118: 16-22, 1992. **Q2**
84. SEVER Z., PAVELIĆ J., LEVANAT S., SPAVENTI R., SLADE N., JELIĆ I., BALTIĆ V., PAVELIĆ LJ., ČABRIJAN T., ČASL T., PAVELIĆ K., Insulin-related substances in human solid tumors. **Tumordiagn. u. Ther.** 13: 54-59, 1992. **Q4**
85. OSMAK M., PEĆINA N., PAVELIĆ K., Multiple fractions of gamma rays increase the expression of p62<sup>c-myc</sup> in Chinese hamster V79 cells. **Period. biol.** 94: 59-64, 1992. **Q3**
86. ŠTORGĀ D., PEĆINA-ŠLAUS N., PAVELIĆ J., PAVELIĆ Z.P., PAVELIĆ K., *c-fms* is present in primary tumours as well as in their metastases in bone marrow. **Int J. Exp. Path.** 73: 527-533, 1992. **Q1**
87. POLJAK LJ., VERSTOVŠEK S., KNEŽEVIĆ N., UŽAREVIĆ B., BATINIĆ D., PAVELIĆ K., MARUŠIĆ-GALEŠIĆ S., Cyclosporine A differently affects the function of the two Main T cell subsets. **Croatian Med. J.** 33: 102-106, 1992. **Q2**
88. PAVELIĆ K., ANTONIĆ M., PAVELIĆ LJ., PAVELIĆ J., PAVELIĆ Z., SPAVENTI Š., Human lung cancers growing on extracellular matrix: Expression of oncogenes and growth factors. **Anticancer Res.** 12: 2191-2196, 1992. **Q2**
89. GRAZIO S., FRKOVIĆ-GRAZIO S., ČABRIJAN T., ZJAČIĆ-ROTKVIĆ V., GOLDONI V., PEĆINA-ŠLAUS N., KAMENJICKI E., PAVELIĆ K., Freshly frozen subsequently AMeX processed breast carcinoma tissue - a new possibility for immunohistochemical detection of c-myc oncoprotein. **Period. biol.** 94: 215-220, 1992. **Q3**
90. KAPITANOVIĆ S., SPAVENTI R., KUŠIĆ B., PAVELIĆ K., *c-erbB-2/neu* in colorectal carcinoma: A potential prognostic value? **Eur. J. Cancer**, 29A: 170-170, 1993. **Q1**
91. GALL-TROŠELJ K., PAVIČIĆ D., AUDY-JURKOVIĆ S., PAVELIĆ J., PAVELIĆ K., PCR amplification of DNA from stained cytological smears. **J. Clin. Pathol.** 46: 378-379, 1993. **Q1**
92. HORVAT Š., HORVAT J., VARGA-DEFTERDAROVIĆ L., PAVELIĆ K., CHUNG N.N., SCHILLER P.W. Methionine-enkephalin related glycoconjugates. Synthesis and biological activity. **Int. J. Peptide Protein Res.** 41: 399-404, 1993. **Q3**
93. PUJIĆ N., HEGEDIS LJ., PAVELIC K., CASL T., MARUSIC S., SAVOVSKI K., DUJIC A., DIMITRIJEVIC B., Humoral stimulating activities in post-cyclophosphamide rat sera and their purified fractions. **Cell Prolif.** 26: 1-11, 1993. **Q3**

94. GALL K., PAVELIĆ J., JADRO-ŠANTEL D., POLJAK M., PAVELIĆ K. DNA amplification by polymerase chain reaction from brain tissues embedded in paraffin. **Int. J. Exp. Path.** 74: 333-337, 1993. **Q1**
95. POLJAK LJ., PEĆINA N., DŽUBUR A., UŽAREVIĆ B., VITALE B., PAVELIĆ K.: Modulation of p62c-myc expression in a single case of non-T acute lymphoblastic leukemia (ALL) assessed by image analyzer. **Tumordiagn. u.Ther.** 14:158-162,1993. **Q4**
96. PAVELIĆ K, BANJAC Ć, PAVELIĆ J, SPAVENTI Š.: Evidence for a role of EGF receptor in the progression of human lung carcinoma. **Anticancer Res.** 13:1133-1138, 1993. **Q2**
97. SPAVENTI R., PEČUR L., PAVELIĆ K., PAVELIĆ Z.P., SPAVENTI Š., STAMBROOK P.J.: Human Tumour Bank in Croatia: a Possible Model for a Small Bank as a Part of the Future European Tumour Bank Network. **Eur. J. Cancer** 30A:419-419, 1994. **Q1**
98. KAPITANOVIĆ S., SPAVENTI R., POLJAK LJ., KAPITANOVIĆ M., PAVELIĆ Z.P., GLUCKMAN J.L., SPAVENTI Š., PAVELIĆ K.: High c-erbB-2 protein level in colorectal adenocarcinomas correlates with clinical parameters. **Cancer Detect. Prevent.** 18: 97-101,1994.
99. KNEŽEVIĆ V., SPAVENTI R., POLJAK LJ., SLADE N., ŠVAJGER A., PAVELIĆ K.: p185<sup>neu</sup> is expressed in yolk sac during rat postimplantation development. **J. Anat.** 185: 181-187, 1994. **Q1**
100. SPAVENTI R., PAVELIĆ K., PAVELIĆ Z.P., GLUCKMAN J.L.: The concomitant expression of oncogenes and growth factors in human breast cancer. **Eur. J. Cancer** 30A:723-724, 1994. **Q1**
101. SPAVENTI R., KAMENJICKI E., PECINA N., GRAZIO S., GRAZIO S., PAVELIC J., KUSIC B., CVRTILA D., DANIOVIC Z, SPAVENTI S., PAVELIC K., GLUCKMAN J., PAVELIC Z.P.: Immunohistochemical detection of TGF-a, EGF-R, *c-erbB-2*, *c-H-ras*, *c-myc*, estrogen and progesterone in benign and malignant human breast lesions: A concomitant expression? **In vivo** 8:183-190, 1994.
102. PAVELIĆ J., GALL-TROŠELJ K., HLAVKA V., PAVELIĆ Z.P., GLUCKMAN J.L., STAMBROOK P.J., PAVELIĆ K.: nm23-H1 protein in oligodendrogiomas. **Int. J. Oncol.** 4:1399-1403, 1994. **Q2**
103. PEĆINA-ŠLAUS N., PAVELIĆ J., PAVELIĆ K.: Comparison of reverse-phase HPLC and gel electrophoretic purification of synthetic oligonucleotides. **Period. biol.** 96:161-164, 1994. **Q3**
104. ILIJAS M., PAVELIC K., SARCEVIC B., KAPITANOVIC S., KURJAK A., STAMBROOK P.J., GLUCKMAN J.L., PAVELIC Z.P.: Expression of nm23-H1 gene in squamous cell carcinoma of the cervix correlates with 5-year survival. **Int. J. Oncol.** 5: 1455-1457, 1994. **Q2**
105. SARIC T., SEITZ H.J., PAVELIC K.: Detection of the substance immunologically cross-reactive with insulin in insulin RIA is an artifact caused by insulin tracer degradation: involvement of the insulin-degrading enzyme. **Mol. Cell. Endocrin.**, 106:23-29, 1994. **Q1**
106. PAVELIĆ J., HLAVKA V., POLJAK M., GALE N., PAVELIĆ K.: p53 immunoreactivity in oligodendrogiomas. **J. Neuro-Oncol.** 22:1-6, 1994. **Q1**
107. PAVELIC Z.P., LI Y-Q., STAMBROOK P.J., McDONALD J.S., MUNCK-WIKLAND E., PAVELIC K., DACIC S., DANIOVIC Z., PAVELIC, LJ., MUGGE R.E., WILSON K., NGUYEN C., GLUCKMAN J.L.: Overexpression of p53 protein is common in premalignant head and neck lesions. **Anticancer Res.** 14: 2259-2266, 1994. **Q2**

108. PECUR L., KAPITANOVIĆ S., SONICKI Z., PAVIČIĆ F., SPAVENTI Š., SPAVENTI R., GLUCKMAN J.L., STAMBROOK P.J., PAVELIC Z.P., SPAVENTI R., PAVELIC K.P.: Prognostic significance of transforming growth factor alpha (TGF-a) in human lung carcinoma: An immunohistochemical study. *Anticancer Res.* 14:2839-2844, 1994. **Q2**
109. PAVELIC Z.P., LI Y-Q., STAMBROOK P.J., MUNCK-WIKLAND E., PAVELIC K., McDONALD J.S., DACIC S., DANILOVIC Z., PAVELIC, LJ., MUGGE R.E., WILSON K., NGUYEN C., KLUSMAN P., GLUCKMAN J.L.: p53 mutation and expression during multistage human head and neck carcinogenesis. *Proceedings of the XVI International Cancer Congress*, New Delhi, India, 30.10.-5.5.1994. edited by R.S. Rao, M.G. Deo and L.D. Sanghvi. Monduzzi Editore S.p.A. Bologna, 923-927, 1994.
110. SLADE N., PAVELIĆ J., KRUŠLIN B., PAVELIĆ K.: Type IV collagenase in squamous cell and basal cell skin carcinomas. *Arch. Dermat. Res.* 287:512-514, 1995. **Q1**
111. GRDIŠA M., KRALJ M., ECKERT-MAKSIĆ M., MAKSIĆ Z.B. 6-amino-6-deoxyascorbic acid induces apoptosis in human tumor cells. *J. Cancer Res. Clin. Oncol.*, 121:98-102, 1995. **Q2**
112. KAPITANOVIĆ S., SPAVENTI R., VUJISIĆ S., PETROVIĆ Z., KURJAK A., PAVELIĆ Z.P., GLUCKMAN J.L., STAMBROOK P.J., PAVELIC K. nm23-H1 gene expression in ovarian tumors - a potential tumor marker. *Anticancer Res.*, 15:587-590, 1995. **Q2**
113. GALL-TROŠELJ K., KUŠIĆ B., PEĆINA-ŠLAUS, N., PAVELIĆ K., PAVELIĆ J. Nested polymerase chain reaction for detection of hepatitis C virus RNA in blood derivatives. *Eur J Clin Chem Clin Biochem*, 33:733-736, 1995.
114. SLADE N., KUZMIĆ I., POLJAK LJ., KRUŠLIN B., PAVELIĆ K., PAVELIĆ J. Inverse relation between type IV collagenase and TGF-b1 in human endometrial carcinoma. *Tumordiagn. u. Ther.* 16:230-231, 1995. **Q4**
115. PAVELIĆ K., HRAŠČAN R., KAPITANOVIĆ S., KARAPANDŽA N., VRANEŠ Z., BELICZA M., KRUŠLIN B., ČABRIJAN T. Multiple genetic alterations in malignant metastatic insulinomas. *J. Pathol.*, 178:395-400, 1995. **Q1**
116. PAVELIĆ K. Human tumor bank. *Period. Biol.* 97:11-12, 1995. **Q3**
117. KRALJ M., KOJIĆ-PRODIĆ B., BANIĆ Z., GRDIŠA M., VELA V., ŠUŠKOVIĆ B., PAVELIĆ K. Synthesis, structural characterization and cytotoxic effect of 6-amino-6-deoxy-L-ascorbic acid derivatives. *Eur. J. Med. Chem.* 31:23-35, 1996. **Q1**
118. PAVELIĆ K. Is tumor suppressor gene p53 involved in neuroendocrine tumor carcinogenesis. *J. Pathol.* 178:359-360, 1996. **Q1**
119. PAVELIĆ J., GALL-TROŠELJ K., HERAK-BOSNAR M., KARDUM M.M., PAVELIĆ K.: PCR amplification of DNA from archival specimens. A methodological approach. *Neoplasma*, 43:75-81, 1996. **Q3**
120. GRCE M., MAGDIĆ L., KOCIJAN I., PAVELIĆ K. Increase of genital human papillomavirus infection among men and women in Croatia. *Anticancer Res.*, 16:1039-1042, 1996. **Q2**
121. PAVELIĆ K., HRASCAN R., KAPITAONOVIC S., VRANES Z., CABRIJAN T., SPAVENTI S., KORSIC M., KRIZANAC S., LI Y.Q., STAMBROOK P., GLUCKMAN J.L., PAVELIC Z.P.: Molecular genetics of malignant insulinoma. *Anticancer Res.*, 16:1707-1718, 1996. **Q2**
122. HRAŠČAN R., PAVELIĆ K., PAVIČIĆ F., KRIŽANAC Š., ŠTAJCER-ŠТИЋ, V., PEĆUR L., SPAVENTU Š., KLIMPFINGER M., PAVELIĆ J: Concomitant point mutation of tumor suppressor gene p53 and oncogene c-N-ras in malignant neuroendocrine pancreatic tumor. *Anticancer Res.*, 16:3761-3766, 1996. **Q2**

123. STEINER-BIOCIC, I., GLAVAS-OBROVAC, L. KARNER, I., PIANTANIDA, I., ZINIC, M., PAVELIC, K., PAVELIC, J.: 4,9-Diazapyrenium dications induce apoptosis in human tumor cells. **Anticancer Res.**, 16:3705-3708, 1996. **Q2**
124. KRUŠLIN, B., HRAŠĆAN, R., MANOJLOVIĆ, S., PAVELIĆ, K.: Oncoproteins and tumor suppressor proteins in congenital sacrococcygeal teratomas. **Pediatr. Pathol. Med.**, 17:43-52, 1977.
125. POPOVIĆ-HADŽIJA, M., POLJAK-BLAŽI, M., PAVELIĆ, K.: Presence of c-MYC protein in murine myeloid leukaemia cells during growth and after irradiation. **Anticancer Res.**, 17:1089-1092, 1997. **Q2**
126. GRCE, M., FURČIĆ I., HRAŠĆAN, R., HUSNJAK, K., KRHEN, I., MAREKOVIĆ, Z., ZELJKO Ž., PAVELIĆ, K.: Human Papilloma viruses are not associated with renal carcinoma. **Anticancer Res.**, 17:2193-2196, 1997. **Q2**
127. KAPITANOVIĆ S., RADOŠEVIĆ, S., KAPITANOVIĆ, M., ANĐELINOVICIĆ, Š., FERENČIĆ, Ž., TAVASSOLI, M., PRIMORAC, D., SONICKI Z., SPAVENTI Š., PAVELIĆ, K., SPAVENTI, R.: The expression of p185 HER-2/neu correlates with the stage of disease and survival in colorectal cancer. **Gastroenterology**, 112:1103-1113, 1997. **Q1**
128. GRCE, M., HUSNJAK, K., MAGDIĆ, L., ILIJAŠ, M., ZLAČKI, M., LEPUŠIĆ, D., LUKAČ, J., HODEK, B., GRIZELJ, V., KURJAK, A., KUSIĆ., Z., PAVELIĆ, K.: Detection and typing of human papillomaviruses by polymerase chain reaction in cervical scrapes of Croatian women with abnormal cytology. **Europ. J. Epidemi.**, 13:645-651, 1997. **Q1**
129. HERAK-BOSNAR M., PAVELIĆ, K., HRAŠĆAN, R., ZELJKO Ž., KRHEN I., MAREKOVIĆ, Z., KRIŽANAC, Š., PAVELIĆ, J.: Loss of heterozygosity of the nm23-H1 gene in human renal cell carcinomas. **J. Cancer Res. Clin. Oncol.**, 123:485-488, 1997. **Q2**
130. HERAK BOSNAR, M., PAVELIĆ, K., KRIŽANAC, Š., SLOBODNJAK, Z., PAVELIĆ, J.: Squamous cell lung carcinomas: the role of nm23-H1 gene. **J.Mol. Med.**, 75:609-613, 1997. **Q1**
131. HEĆIMOVIĆ, S., BARIŠIĆ, I., MULLER, A., PETKOVIĆ, I., BARIĆ, I., LIGUTIĆ, I., PAVELIĆ, K.: Expand long PCR for fragile X mutation detection. **Clin. Genet.**, 52:147-154, 1997. **Q2**
132. PAVELIĆ, K., HRAŠĆAN, R., ČABRIJAN, T., KRIŽANAC, D., ELJUGA, D., PAVELIĆ, K., KARAPANDŽA, N., KUSIĆ, Z., SPAVENTI, Š., PAVELIĆ, J.: Point mutation of tumor suppressor gene p53 in two highly malignant metastatic insulinomas. **Tumordiagn. u.Ther.**, 18:102-106, 1997. **Q4**
133. MRAVAK-STIPETIĆ, M., GALL-TROŠELJ, K., LUKAČ, J., KUSIĆ, Z., PAVELIĆ, K., PAVELIĆ, J.: Detection of *Helicobacter pylori* in various oral lesions by nested polymerase chain reaction (PCR). **J. Oral. Pathol. Med.**, 27:1-3, 1998. **Q2**
134. PAVELIĆ, K., ČABRIJAN, T., HRAČŠAN, R., VRKLJAN, M., LIPOVAC, M., KAPITANOVIĆ, S., GALL-TROŠELJ, K., HERAK BOSNAR, M., TOMAC, A., GRŠKOVIĆ, B., KARAPANDŽA, N., PAVELIĆ, LJ., KRUŠLIN, B., SPAVENTI, Š., PAVELIĆ, J.: Molecular pathology of hemangiopericytomas accompanied by severe hypoglycemia: oncogenes, tumor-suppressor genes and the insulin-like growth factor family. **J. Cancer Res. Clin. Oncol.**, 124:307-314, 1998. **Q2**
135. GRDIŠA, M., LOPOTAR, N., PAVELIĆ, K.: Effect of a 17-member azalide on tumor cell growth. **Chemotherapy** 44:331-336, 1998. **Q2**

136. HEĆIMOVIĆ, S., BARIŠIĆ, I., PAVELIĆ, K.: DNA analysis of the fragile X syndrome in an at risk pediatric population in Croatia: simple clinical preselection criteria can considerably improve the cost-effectiveness of fragile X screening studies. **Human Hered.**, 48:256-265, 1988. **Q2**
137. ILIJAŠ, M., KAPITANOVIĆ, S., ŠARČEVIĆ, B., PAVELIĆ, K., PAVELIĆ, Z.P., KURJAK, A., PAVELIĆ J.: Gene nm23-H1 - possible prognostic factor for invasive squamous cell carcinoma of cervix uteri. **J. Tumour Marker Oncol.**, 13:61-67, 1998. **Q4**
138. PAVELIĆ, J., GALL-TROŠELJ, K., MRAVAK-STIPETIĆ, M., PAVELIĆ, K.: The p53 and nm23-H1 Genes are not Deleted in Oral Benign Epithelial Lesions. **Anticancer Res.**, 18:3527-3532, 1998. **Q2**
139. HEĆIMOVIĆ, S., BARIŠIĆ, I., MARKOVIĆ, D., ŠKARPA, I., RELJA, M., PAVELIĆ, K.: Trinucleotide repeat diseases - DNA molecular analysis using a simple expand long PCR assay. **Period. biol.**, 100: 353-360, 1998. **Q3**
140. ŠTURLAN, S., KAPITANOVIĆ, S., KOVAČEVIĆ, D., LUKAČ, J., SPAVENTI, Š., SPAVENTI, R., PAVELIĆ, K.: Loss of heterozygosity of APC and DCC tumor suppressor genes in human sporadic colon cancer. **J. Mol. Med.**, 77: 316-321, 1999. **Q1**
141. PAVELIĆ, K., PAVELIĆ, Z.P., ČABRIJAN, T., KARNER, I., SAMARŽIJA, M., STAMBROOK, P.J.: Insulin-like growth factor family in malignant haemangiopericytomas: the expression and role of insulin-like growth factor I receptor. **J. Pathol.**, 188: 69-75, 1999. **Q1**
142. KATIĆ, M., HADŽIJA, M., WRISCHER, M., PAVELIĆ, K.; An in vitro model of the early genetic events in multistage carcinogenesis of malignant insulinoma. **Carcinogenesis**, 20: 1521-1527, 1999. **Q1**
143. RAIĆ-MALIĆ, S., HERGOLD-BRUNDIĆ, A., NAGL, A., GRDIŠA, M., PAVELIĆ, K., DE CLERCQ, E., MINTAS, M.: Novel pyrimidine and purine derivatives of L-ascorbic Acid: synthesis and biological evaluation. **J. Med. Chem.**, 42: 2673-2678, 1999. **Q1**
144. PEĆINA-ŠLAUS, N., PAVELIĆ, K., PAVELIĆ, J.: Loss of heterozygosity and protein expression of APC gene in renal cell carcinomas. **J. Mol. Med.**, 77: 446-453, 1999. **Q1**
145. PAVELIĆ K., SPAVENTI Š., GLUNČIĆ V., MATEJČIĆ A., PAVIČIĆ D., KARAPANDŽA N., KUSIĆ Z., LUKAČ J., ČABRIJAN T., PAVELIĆ J.: The expression and role of insulin-like growth factor II in malignant hemangiopericytomas. **J. Mol. Med.**, 77:865-869,1999. **Q1**
146. SLADE N., ŠTORGA-TOMIĆ D., BIRKMAYER GD., PAVELIĆ K., PAVELIĆ J: Effect of extracellular NADH on human tumor cell proliferation. **Anticancer Res.**, 19:5355-5360,1999. **Q2**
147. RAIĆ-MALIĆ S., GRDIŠA M., PAVELIĆ K., MINTAS M.: Synthesis and biological evaluation of the novel purine and pyrimidine nucleoside analogues containing 2,3-epoxypropyl, 3-amino-2-hydroxypropyl or 2,3-epoxypropyl ether moieties. **Eur. J. Med. Chem.**, 34: 405-413,1999. **Q1**
148. PAVELIĆ K.: Molecular Genetics of Malignant Insulinomas. In: **Diseases of Pancreas, Biliary Tract and Duodenum**. Day of Dialogue in Diagnostic Dilemmas (edited by. Ferlan-Marolt V., Luzar B., Pavelić K., Vučelić B.) Institute of Pathology, Medical Faculty University of Ljubljana, Ljubljana, Slovenia,1999.
149. PAVELIĆ, K., KAPITANOVIĆ, S., BURA, M., SEIWERTH, S., PAVELIĆ, LJ., SPAVENTI, R.: Increased activity of nm23-H1 gene in squamous cell carcinoma of the head and neck is associated with advanced disease and poor prognosis. **J. Mol. Med.**, 78:111-118, 2000. **Q1**

150. KAPITANOVIĆ S., RADOŠEVIĆ S., SLADE N., KAPITANOVIĆ M., ANĐELINović Š., FERENČIĆ Ž., TAVASSOLI M., SPAVENTI Š., PAVELIĆ K., SPAVENTI R.: Expression of erbB-3 protein in colorectal adenocarcinoma: correlation with poor survival. **J. Cancer Res. Clin. Oncol.**, 126:205-211, 2000. **Q2**
151. GROET J., IVES J.H., JONES T.A., DANTON M., FLOMEN R.H., SHEER D., HRAŠĆAN R., PAVELIĆ K., NIŽETIĆ D.: Narrowing of the region of allelic loss in 21q11-21 in squamous non-small cell lung carcinoma and cloning of a novel ubiquitin-specific protease gene from the deleted segment. **Genes, Chromosomes & Cancer**, 27:153-161, 2000. **Q1**
152. PAVELIĆ J., LAMOVEC J., NOVAK J., GALL-TROŠELJ K., KAPITANOVIĆ S., PAVELIĆ K.: Collision tumour in the pelvic cavity: rectal leiomyosarcoma and prostate adenocarcinoma. **J Cancer Res. Clin. Oncol.**, 126:95-100, 2000. **Q2**
153. ROKNIĆ S., GLAVAŠ-OBROVAC LJ., KARNER I., PIANTANIDA I., ŽINIĆ M., PAVELIĆ K.: In vitro cytotoxicity of three 4,9-diazapyrenium hydrogensulfate derivatives on different human tumor cell lines. **Cancer Therapy**, 46:143-149, 2000. **Q2**
154. GRCE M., HUSNJAK K., SKERLEV M., LIPOZENČIĆ J., PAVELIĆ K.: Detection and typing of human papillomaviruses by means of polymerase chain reaction and fragment length polymorphism in male genital lesions. **Anticancer Res.** 20:2097-2102, 2000. **Q2**
155. COLIC M., PAVELIC, K.: Molecular mechanisms of anticancer activity of natural dietetic products. **J. Mol. Med.**, 78:333-336, 2000. **Q1**
156. HUSNJAK K., GRCE M., MAGDIĆ L., PAVELIĆ K. Comparison of five different polymerase chain reaction methods for detection of human papillomavirus in cervical cell specimens. **J. Virol. Methods**, 88:125-134, 2000. **Q3**
157. RAVLIĆ-GULAN J., RADOŠEVIĆ-STAŠIĆ B., GULAN G., ŠTIMAC D., PAVELIĆ K., RUKAVINA D.: Immunoprotective properties of peptidoglycan monomer linked with zinc in cholestatic jaundice. **Int. Arch. Allergy Immunol.** 123:354-364, 2000.
158. PAVELIĆ K., HADŽIJA M., BEDRICA LJ., PAVELIĆ J., ĐIKIĆ I., KATIĆ M., KRALJ M., HERAK BOSNAR M., KAPITANOVIĆ S., POLJAK-BLAŽI M., KRIŽANAC Š., STOJKOVIĆ R., JURIN M., SUBOTIĆ B., ČOLIĆ M.: Natural zeolite clinoptilolite: new adjuvant in anticancer therapy. **J. Mol. Med.** 78:708-720, 2001. **Q1**
159. KRALJ M., KAPITANOVIĆ S., KOVAČEVIĆ D., LUKAČ J., SPAVENTI Š., PAVELIĆ K.: Effect of the nonsteroidal anti-inflammatory drug indomethacin on proliferation and apoptosis of colon carcinoma cells. **J. Cancer Res. Clin. Oncol.**, 127:173-179, 2001. **Q2**
160. POPOVIĆ HADŽIJA M., KAPITANOVIĆ S., RADOŠEVIĆ S., ČAČEV T., MIRT M., KOVAČEVIĆ D., LUKAČ J., HADŽIJA M., SPAVENTI R., PAVELIĆ K.: Loss of heterozygosity of DPC4 tumor suppressor gene in human sporadic colon cancer. **J. Mol. Med.** 79:128-132, 2001. **Q1**
161. GRCE M., HUSNJAK K., BOŽIKOV J., MAGDIĆ L., ZLAČKI M., LUKAČ J., FISTONIĆ I., ŠIKANIĆ-DUGIĆ N., PAVELIĆ K.: Evaluation of genital human papillomavirus infections by polymerase chain reaction among Croatian women. **Anticancer Res.**, 21:579-584, 2001. **Q2**
162. POLJAK-BLAŽI M., KATIĆ M., KRALJ M., ŽARKOVIĆ N., MAROTTI T., BOŠNJAK B., ŠVERKO V., BALOG T., PAVELIĆ K.: *In vitro* and *in vivo* effect of natural clinoptilolite on malignant tumors. **Stud. Surf. Sci. Catal.** 135:5309-5316, 2001. **Q3**
163. K. PAVELIĆ K., SUBOTIĆ B., ČOLIĆ M.: Biomedical applications of zeolites. **Stud. Surf. Sci. Catal.** 135:5309-5316, 2001. **Q3**

164. KAPITANOVIĆ S., ČAČEV T., SPAVENTI R., PAVELIĆ K.. Submerged gel electrophoresis on sephadex gels- a new method for APC gene mutation detection. **J. Mol. Med.**, 79:333-337, 2001. **Q1**
165. PAVELIĆ K., KRIŽANAC Š., ČAČEV T., POPOVIĆ HADŽIJA M., RADOŠEVIĆ S., CRNIĆ I., LEVANAT S., KAPITANOVIĆ S.: Aberration of FHIT gene is associated with increased tumor proliferation and decreased apoptosis – clinical evidence in lung and head and neck carcinomas. **Molecular Medicine**, 7: 442-453, 2001. **Q1**
166. GLAVAS-OBROVAC LJ., KARNER I., ZINIC B., PAVELIC K.: Antineoplastic activity of novel N-1-sulfonypyrimidine derivatives. **Anticancer Res.**, 21:1979-1986, 2001. **Q2**
167. PAVELIĆ K., GALL-TROŠELJ K.: Recent advances in molecular genetics of breast cancer. **J. Mol. Med.**, 79:566-573, 2001. **Q1**
168. HEĆIMOVIĆ S., VLAŠIĆ J., BARIŠIĆ I., MARKOVIĆ D., ČULIĆ V., PAVELIĆ K.: A simple and rapid analysis of triplet repeat diseases by expand long PCR. **Clin. Chem. Lab. Med.** 39:1259-1262, 2001. **Q1**
169. PAVELIĆ K., KATIĆ M., ŠVERKO V., MAROTTI T., BOŠNJAK B., BALOG T., STOJKOVIĆ R., RADAČIĆ M., ČOLIĆ M., POLJAK-BLAŽI M.. Immunostimulatory effect of natural clinoptilolite as a possible mechanism of its antimetastatic ability. **J. Canc. Res. Clin. Oncol.**, 128:37-44, 2002. **Q2**
170. HEĆIMOVIĆ S., BAGO R., MUŽINIĆ D., BEGOVIĆ D., PAVELIĆ K.: The first case of the FRAXE form of inherited mental retardation in Croatia. **Eur. J. Pediatr.** 161:112-113 , 2002. **Q2**
171. HEĆIMOVIĆ S., PETEK TARNIK I., BARIĆ I., ČAKARUN Ž., PAVELIĆ K.: Screening for fragile X syndrome: results from a school for mentally retarded children. **Acta Paediatr.** 91:535-539, 2002.
172. HEĆIMOVIĆ S., KLEPAC N., VLAŠIĆ J., VOJTA A., JANKO D., ŠKARPA-PRPIĆ I., CANKI-KLAIN N., MARKOVIĆ D., BOŽIKOV J., RELJA M., PAVELIĆ K.: Genetic background of Huntington disease in Croatis: Molecular analysis of CAG, CCG, and d2642 (E2642del) polymorphysms. **Human Mutation** #526 2002. **Q1**
173. PAVELIĆ J., PAVELIĆ LJ., KARADŽA J., KRIŽANAC Š., UNEŠIĆ J., SPAVENTI Š., PAVELIĆ K.: Insulin-like growth factor family and combined antisense approach in therapy of lung carcinoma. **Molecular Medicine** 8:149-157, 2002. **Q1**
174. PEĆINA-ŠLAUS N., GALL-TROŠELJ K., KAPITANOVIĆ S., PAVELIĆ J., PAVELIĆ K.: Novel alleles of the D16S752 polymorphic genetic marker linked to E-Cadherin Gene – A potential population marker. **Coll. Antropol.** 26:85-88, 2002. **Q2**
175. PAVELIĆ K., BUKOVIĆ D., PAVELIĆ J.: The role of insulin-like growth factor 2 and its receptors in human tumors. Review. **Molecular Medicine**, 8:771-780, 2002. **Q1**
176. DOGAN-KORUŽNJAČ J., SLADE N., ZAMOLA B., PAVELIĆ K., KARMINSKI-ZAMOLA G.: Synthesis, photochemical synthesis and antitumor evaluation of novel derivatives of thieno(3',2':4,5)thieno(2,3-c)quinolones. **Chem. Pharm. Bull.**, 50:656-660, 2002. **Q2**
177. COLIC M., PAVELIC K.: Molecular, cellular and medical aspects of the action of nutraceuticals and small molecules therapeutics: from chemoprevention to new drug development. **Drugs Exptl. Clin. Res.** 26:169-175, 2002.
178. COLIC M., PAVELIC K.: Cellular mechanisms of immunomodulatory activities of silicate materials. **J. Tumour Marker Oncol.**, 18:63-68, 2002. **Q4**

179. DZOLIC Z., KRISTOFOR V., CETINA M., NAGL A., HERGOLD-BRUNDIC D., MRVOS-SERMEK T., BURGEMEISTER M., GRDISA N., SLADE K., PAVELIC K., BALZARINI J., DECLERCQ E., MINTAS M.: Synthesis, structural studies and biological evaluation of some purine substituted 1.aminocyclopropane-1-carboxylic acids and 1-amino-1-hydroxymethylcyclopropanes. **Nucleosides Nucleotide & Nucleic Acid** 22:373-389, 2003. **Q2**
180. ZARKOVIC N., ZARKOVIC K., KRALJ M., BOROVIC S., SABOLOVIC S., POLJAK BLAZI M., CIPAK A., PAVELIC K.: Anticancer and antioxidative effects of micronized zeolite clinoptilolite. **Anticancer Res.** 23:1589-1596, 2003. **Q2**
181. DZOLIC Z., CETINA M., KOVACEK D., HERGOLD-BRUNDIC A., MRVOS-SERMEK D., NAGL A., SLADE N., PAVELIC K., BALZARINI J., DE CLERCQ E., ZERBE O., FOLKERS G., SCAPOZZA L., MINTAS M.: Molecular structures and ab initio molecular orbital calculations of the optically active derivatives of 1-aminocyclopropane-1-carboxylic acid. **J. Mol. Struct.** 655:229-241, 2003. **Q3**
182. SARIC T., MULLER D., SEITZ H.J., PAVELIC K.: Non-covalent interaction of ubiquitin with insulin-degrading enzyme. **Mol. Cell. Endocrinol.** 204:11-20, 2003. **Q1**
183. DOGAN KORUZNJAK J., GRDISA M., SLADE N., ZAMOLA B., PAVELIC K., KARMINSKI-ZAMOLA G.: Novel derivatives of benzo(b)thienol(2,3-c)quinolones: synthesis, photochemical synthesis and antitumor evaluation. **J. Med. Chem.** 46:4516-4524, 2003. **Q1**
184. KRALJ M., PAVELIĆ K.: Medicine on a small scale. How molecular medicine can benefit from self-assembled and nanostructured materials? **EMBO Rep.** 4: 1008-1012, 2003. **Q1**
185. HRANJEC M., GRDIŠA M., PAVELIĆ K., BOYKIN D.W., KARMINSKI-ZAMOLA G.: Synthesis and antitumor evaluation of some new substituted amidino-benzimidazolyl-furyl-phenyl-acrylates and naphthol/2,1,-*b*/furan-carboxylates. **II Farmaco** 58:1319-1324, 2003. **Q2**
186. PAVELIC K., KOLAK T., KAPITANOVIC S., RADOSEVIC S., SPAVENTI S., KRUSLIN B., PAVELIC J.: Gastric cancer: the role of insulin-like growth factor 2 (IGF 2) and its receptors (IGF 1R and M6-P/IGF 2R). **J. Pathol.** 201:430-438, 2003. **Q1**
187. PREKUPEC S., SVEDRUŽIĆ D., GAZIVODA T., MRVOŠ-SERMEK D., NAGL A., GRDIŠA M., PAVELIĆ K., BALZARINI J., DECLERCQ E., FOLKERS G., SCAPOZZA L., MINTAS M., RAIĆ-MALIĆ S.: Synthesis and biological evaluation of iodinated and fluorinated 9-(2-hydroxypropyl) and 9-(2-hydroxyethoxy)methyl purine nucleoside analogues. **J. Med. Chem.**, 46:5763-5772, 2003. **Q1**
188. PAVELIĆ K., HADŽIJA M.: Medical application of zeolites. In: **Handbook of Zeolite Science and Technology**. (edited by Auerbach S.M., Carrado K.A., Dutta P.K.) Marcel Dekker, New York, 1141-1172, 2003.
189. GRCE M., HUSNJAK K., MATOVINA M., MILUTIN N., MAGDIĆ L., HUSNJAK K., PAVELIC, K.: Human papillomavirus, cytomegalovirus, and adeno-associated virus infections in pregnant and nonpregnant women with cervical intraepithelial neoplasia. **J. Clin. Microbiol.** 42:1341-1344, 2004. **Q1**
190. POPOVIĆ-HADŽIJA M., RADOŠEVIC S., KOVAČEVIĆ D., LUKAČ J., HADŽIJA M., SPAVENTI R., PAVELIĆ K., KAPITANOVIĆ S.: Status of the DPC4 tumor suppressor gene in sporadic colon adenocarcinoma of Croatian patients: identification of a novel somatic mutation. **Mutation Res.** 548:61-73, 2004. **Q1**
191. RAIC-MALIC.S., TOMASKOVIC L., MRVOS-SERMEK D., PRUGOVECKI B., CETINA M., GRDISA M., PAVELIC K., MANNSCHERECK A., BALZARINI J., DE CLERCQ E., MINTAS M.:

- Spirobipyridopyrans, spirobinaphthopyrans, indolinospiropyridopyrans, indolinospironaphthopyrans and indoliunospironaphtho-1,4,-oxazines: synthesis, study of X-ray crystal structure, antitumoral and antiviral evaluation. **Bioorganic Medicinal Chemistry** 12: 1037-1045, 2004. **Q1**
192. KOWANETZ K., HUSNJAK K., HOLLER D., KOWANETZ M., SOUBEZRAN P., HIRSCH D., SCHMIDT M.H.H., PAVELIC K., DE CAMILLI P., RANDAZZO P.A., DIKIC I.: CIN85 associates with multiple effectors controlling intracellular trafficking of EGF receptors. **Mol. Biol. Cell.**, 15:3155-3166, 2004. **Q1**
193. ĆALETIĆ I., GRDIŠA M., MRVOŠ-SERMEK D., CETINA M., TRALIĆ-KULENOVIĆ V., PAVELIĆ K., KARMINSKI-ZAMOLA G.: Synthesis, crystal structure and antiproliferative evaluation of some new substituted benzothiazoles and styrylbenzothiazoles. **II Farmaco.** 59:297-305, 2004. **Q2**
194. PEĆINA-ŠLAUS N., GALL-TROŠELJ K., ŠLAUS M., RADIĆ K., NIKUŠEVA-MARTIĆ T., PAVELIĆ K.: Genetic changes of the E-cadherin and APC tumor suppressor genes in clear cell renal cell carcinoma. **Pathology** 36: 1-7, 2004. **Q1**
195. KRALJEVIC S., STAMBROOK P.J., PAVELIC K.: Accelerating drug discovery. **EMBO Rep.** 5: 837-842, 2004. **Q1**
196. BATINAC S., MRVOŠ SERMEK D., CETINA M., PAVELIĆ K., MINTAS M., RAIĆ-MALIĆ S.: Synthesis of the novel bicyclic oxepinopyrimidine and fluorinated pyrrolidinopyrimidines. **Heterocycles**, 63:2523-2536, 2004. **Q3**
197. KAPITANOVIĆ S., ČAČEV T., RADOŠEVIĆ S., SPAVENTI Š., SPAVENTI R., PAVELIĆ K.,: APC gene loss of heterozygosity, mutations, E1317Q, and I1317K germ-line variants in sporadic colon cancer in Croatia. **Exp. Mol. Pathol.** 77:193-200, 2004. **Q1**
198. POPOVIĆ-HADŽIJA M., HRAŠČAN R., HERAK-BOSNAR M., ZELJKO Ž., HADŽIJA M., ČADEŽ J., PAVELIĆ K., KAPITANOVIĆ S.: Infrequent alterations of the DPC4 tumor-suppressor gene in renal cell carcinoma. **Urolog. Res.** 32:229-235, 2004.
199. KAPITANOVIĆ S., ČAČEV T., BERKOVIĆ M., POPOVIĆ-HADŽIJA M., RADOŠEVIĆ S., SEIWERTH S., SPAVENTI Š., PAVELIĆ K., SPAVENTI R.: nm23-H1 expression and loss of heterozygosity in colon adenocarcinoma. **J. Clin. Pathol.** 57: 1312-1318, 2004. **Q1**
200. JARAK I., KRALJ M., ŠUMAN L., PAVLOVIĆ G., DOGAN J., PAVELIĆ K., KARMINSKI-ZAMOLA G.: 2-carboxanilides and benzo(b) thieno(2, 3-c)quinolones: synthesis, photochemical synthesis, crystal structure determination and antitumor evaluation. Part 2. **J. Med. Chem.** 48:2346-2360, 2005. **Q1**
201. PREKUPEC S., KALOKIRA B., GRDIŠA M., PAVELIĆ K., DECLERCQ E., MINTAS M., RAIĆ-MALIĆ S. Synthesis and comparative cytostatic activity of the new N-7 acyclic purine nucleoside analogues with natural N-9 regioisomers. **Heterocycles** 65:787-797, 2005. **Q3**
202. OPAČIĆ N., BARBARIĆ M., ZORC B., CETINA M., NAGL A., FRKOVIĆ D., KRALJ M., PAVELIĆ K., BALZARINI J., ANDREI G., SNOECK R., DE CLERCQ E., RAIĆ-MALIĆ S., MINTAS M.: The novel L- and D-amino acid derivatives of hydroxyurea and hydantoins: synthesis, X-ray crystal structure study, cytostatic and antiviral evaluations. **J. Med. Chem.**, 48:475-482, 2005. **Q1**
203. PAVELIĆ J., KRIŽANAC Š., KAPITANOVIĆ S., PAVELIĆ LJ., SAMARŽIJA M., PAVIČIĆ F., SPAVENTI Š., JAKOPOVIĆ M., HERCEG-IVANOVIĆ Z., PAVELIĆ K.: The consequences of insulin-like growth factors/receptors dysfunction in lung cancer. **Am. J. Respir. Cell Mol. Biol.**, 32: 65-71, 2005. **Q1**

204. KRALJ M., KRALJEVIĆ S., SEDIĆ M., KURJAK A., PAVELIĆ K.: Global approach to perinatal medicine: functional genomics and proteomics. **J. Perin. Med.**, 33 : 5-16, 2005. **Q2**
205. GRCE M., PAVELIĆ K.: Antiviral properties of clinoptilolite . **Micropor. Mesopor. Mater.**, 79:165-169, 2005. **Q1**
206. GAZIVODA T., PLEVNIK M., PLAVEC J., KRALJEVIĆ S., KRALJ M., PAVELIĆ K., BALZARINI J., DE CLERCQ E., MINTAS M., RAIĆ-MALIĆ S.: The novel pyrimidine and purine derivatives of L-ascorbic acid: synthesis, one- and two-dimensional <sup>1</sup>H and <sup>13</sup>C NMR study, cytostatic and antiviral evaluation. **Bior. Med. Chem.** 13: 131-139, 2005. **Q1**
207. BARBARIĆ M., URŠIĆ S., PILEPIĆ V., ZORC B., HERGOLD-BRUNDIĆ A., NAGL A., GRDIŠA M., PAVELIĆ K., SNOECK R., ANDREI G., BALZARINI J., DECLERCQ E., MINTAS M.: Synthesis, X-ray cristal structure study, cytostatic and antiviral evaluation of the novel cycloalkyl-N-aryl-hydroxamic acids. **J. Med Chem** , 48:884-887, 2005. **Q1**
208. PREKUPEC S., MAKUC D., PLAVEC J., KRALJEVIĆ S., KRALJ M., PAVELIĆ K., ANDREI G., SNOECK R., BALZARINI J., DECLERCQ E., RAIĆ-MALIĆ S., MINTAS M.: The novel 5-methyl 6-acyclic chain substituted pyrimidine derivatives: synthesis, 1H and 13C NMR conformational analysis, antiviral and cytostatic evaluation. **Antiviral Chemistry. Chemotherapy..**, 16:327-338, 2005. **Q2**
209. SIROTKOVIĆ-SKERLEV M., KRIŽANAC S., KAPITANOVIĆ S., HUSNJAK K., UNUŠIĆ J., PAVELIĆ K.: Expression of c-myc, erbB-2, p53 and nm23-H1 gene product in benign and malignant breast lesion: Coexpression and correlation with clinicopathologic parameters. **Exp. Mol. Pathol.** 79 : 42-50, 2005. **Q1**
210. ČAČEV T., RADOŠEVIĆ S., SPAVENTI R., PAVELIĆ K., KAPITANOVIĆ S.: NF1 gene loss of heterozygosity and expression analysis in sporadic colon cancer. **Gut**, 54:1129-1135, 2005. **Q1**
211. KRALJEVIĆ S. PAVELIĆ K.: Navigare necesse est. **EMBO Rep** 6 : 695-700, 2005. **Q1**
212. PAVELIĆ K., ETRA A., GALL-TROSELJ K.: Insights from the front lines of nutraceutical research: The Third International Conference on Mechanisms of Action of Nutraceuticals (ICMAN 3). **J. Altern. Complement. Med.** 11: 735-738, 2005. **Q1**
213. MALOJČIĆ G., PIANTANIDA I., MARINIĆ, M., ŽINIĆ M., MARJANOVIĆ M., KRALJ M., PAVELIĆ K., SCHNEIDER-H.-J. : A novel bis-phenanthridine triamine with pH controlled binding to nucleotides and nucleic acid. **Org. Biomol. Chem.** 3:4373-4381,2005. **Q1**
214. KRALJEVIĆ S., SEDIĆ M., PAVELIĆ K.: Cancer research meets functional genomics – what has been accomplished so far? In: **Molecular diagnostic in medicine**. (edited by Luzar B., Poljak M., Glavač D., Balažic J.) Faculty of Medicine University of Ljubljana, Ljubljana, Slovenia 99-108, 2005.
215. KAPITANOVIĆ S., ČAČEV T., ANTICA M., KRALJ M., CAVRIĆ G., PAVELIĆ K., SPAVENTI R.: Effect of indometacin on *E-cahherin* and  $\beta$ -catenin expression in HT-29 colon cancer cells. **Exp. Mol. Path..** 80:91-96, 2006. **Q1**
216. ČAČEV T., JOKIĆ M., SPAVENTI R., PAVELIĆ K., KAPITANOVIĆ S.: Loss of heterozygosity testing using real-time PCR analysis of single nucleotide polymorphism. **J. Canc. Res. Clin. Oncol.** 132:200-204,2006 **Q2**
217. KATIC M., BOŠNJAK B., GALL-TROŠELJ K., DIKIC I., PAVELIC K.: A clinoptilolite effect on cell media and the consequent effects on tumor cells in vitro. **Front. Biosci.** 11:1722-1732, 2006. **Q1**

218. GAZIVODA T., WITTINE K., LOVRIĆ I., MAKUC D., PLAVEC J., CETINA M., MRVOS-SERMEK D., SUMAN L., KRALJ M., PAVELIC K., MINTAS M., RAIC-MALIC S.: Synthesis, structural studies, and cytostatic evaluation of 5,6-di-O-modified L-ascorbic acid derivatives. **Carbohydrate Res.** 341:433-442, 2006. **Q2**
219. JARAK I., KRALJ M., PIANTANIDA I., SUMAN L., ZINIC M., PAVELIC., KARMINSKI-ZAMOLA G.: Novel cyano- and amidino-substituted derivatives of thieno(2,3-b)- and thieno(3,2-b)thiophene-2-carboxanilides and thieno(3',2':4,5)thieno- and thieno(2',3':4,5)thieno(2,3-c)quinolones: Synthesis, photochemical synthesis, DNA binding, and antitumor evaluation. **Bioorgan. Med. Chem.**, 14: 2859-2868, 2006. **Q1**
220. STARČEVIĆ K., KRALJ M., PIANTANIDA I., ŠUMAN L., PAVELIĆ K., KARMINSKI-ZAMOLA G.: Synthesis, photochemical synthesis, DNA binding and antitumor evaluation of novel cyano-and amidino-substituted derivatives of naphtho-furans, naphtho-thiophenes, thieno-benzofurans, benzo-dithiophenes and their acyclic precursors. **Europ. J. Med. Chem.**, 41: 925-939, 2006 **Q1**
221. PAVELIĆ K., PRIMORAC D., VUK-PAVLOVIĆ S.: Integrating new countries into the European Research Area. **EMBO Rep.**, 7 : 458-462, 2006. **Q1**
222. PAVELIĆ K., DEDIVITIS R.A., KAPITANOVIĆ S., ČAČEV T., GUIRADO C.R., DANIC D., RADOSEVIC S., BRKIC K., PEGAN B., KRIZANAC S., KUSIC Z., SPAVENTI S., BURA M.: Molecular genetic alterations of FHIT and p53 genes in benign and malignant thyroid gland lesions. **Mutation Res.** 599: 45-57, 2006. **Q1**
223. KRALJEVIC S., SEDIC M., SCOTT M., GEHRING P., SCHLAPBACH R., PAVELIC K.: Casting light on molecular events underlying anti-cancer drug treatment: What can be seen from the proteomic point of view? **Cancer Treat. Rev.** 32:619-629, 2006. **Q1**
224. KOLUNDŽIĆ R., ORLIĆ D., TRKULJA V., PAVELIĆ K., GALL-TROŠELJ K.: Single nucleotide polymorphism in the interleukin-6 gene promoter, tumor necrosis factor- $\alpha$  gene promoter, and transforming growth factor- $\beta$ 1 gene signal sequence as predictors of time to onset of aseptic loosening after total hip arthroplasty:preliminary study. **J. Orthop. Sci.** 11:592-600, 2006. **Q2**
225. RAJIC Z., ZORC B., RAIC-MALIC S., ESTER K., KRALJ M., PAVELIC K., BALZARINI J., DECLERCQ E., MINTAS M.: Hydantoin derivatives of L- and D-amino acids: Synthesis and evaluation of their antiviral and antitumoral activity. **Molecules** 11:837-848, 2006. **Q1**
226. GAZIVODA T., RAIĆ-MALIĆ S., MARJANOVIĆ M., KRALJ M., PAVELIĆ K., BALZARINI J., DECLERCQ E., MINTAS M.: The novel C-5 aryl, alkenyl substituted uracil derivatives of L-ascorbic acid: Synthesis, cytostatic, and antiviral activity evaluations. **Bioorganic Med. Chem.**, 15:749-758, 2007. **Q1**
227. BARBARIĆ M., KRALJ M., MARJANOVIĆ M., HUSNJAK I., PAVELIĆ K., FILIPOVIĆ-GRČIĆ J., ZORC D., ZORC B.: Santhesis and in vitro antitumor effect of diclofenac and fenoprofen thiolated and nonthiolated polyaspartamide-drug conjugates. **Europ. J. Med. Chem** 42:20-29, 2007. **Q1**
228. KRIŠTAFOR V, RAIĆ-MALIĆ S, CETINA M, KRALJ M, ŠUMAN L, PAVELIĆ K, BALZARINI J, DECLERCQ E, MINTAS M. Santhesis, X-ray crystal structural study, antiviral and cytostatic evaluations of the novel unsaturated acyclic and epoxide nucleoside analogues. **Bioorganic Med. Chem** 14:8126-8138, 2006. **Q1**
229. SIROTKOVIĆ-SKERLEV M., CACEV T., KRIZANAC S., KULIĆ A., PAVELIC K., KAPITANOVIC S.: TNF alpha promoter polymorphism analysis in benign and malignant breast lesions. **Exp. Mol. Pathol.** 83:54-58 (2007) **Q1**

230. STARČEVIĆ K., KRALJ M., ESTER K., SABOL I., GRCE M., PAVELIĆ K., KARMINSKI-ZAMOLA G.: Synthesis, antiviral and antitumor activity of 2-substituted-5-amidino-benzimidazoles. **Bioorganic Med. Chem.** 15:4419-4426, 2007. **Q1**
231. PREKUPEC S., MAKUC D., PLAVEC J., ŠUMAN L., KRALJ M., PAVELIĆ K., BALZARINI J., DE CLERCQ E., MINTAS M., RAIĆ-MALIĆ S. Novel C-6 fluorinated acyclic side chain pyrimidine derivatives: synthesis, 1H and 13C NMR conformational studies, and antiviral and cytostatic evaluation. **J. Med. Chem.** 50:3037-3045, 2007. **Q1**
232. GAZIVODA T., ŠOKČEVIĆ M., KRALJ M., ŠUMAN L., PAVELIĆ K., DECLERCQ E., ANDREI G., SNOECK R., BALZARINI J., MINTAS M., RAIĆ-MALIĆ S.: Synthesis and antiviral and cytostatic evaluations of the new C-5 substituted pyrimidine and furo(2,3-*d*)pyrimidine 4',5'-didehydro-L-ascorbic acid derivatives. **J. Med. Chem.** 50:4105-4112, 2007. **Q1**
233. HRANJEC M., KRALJ M., PIANTANIDA I., SEDIĆ M., ŠUMAN L., PAVELIĆ K., KARMINSKI-ZAMOLA G.: Novel cyano- and amidino-substituted derivatives of styryl-2-benzimidazoles and benzimidazol/1,2- $\square$ )quinolines. Synthesis, photochemical synthesis, DNA-binding, and antitumor evaluation, Part 3. **J. Med. Chem.** 50:5696-5711, 2007. **Q1**
234. PAVELIC J, RADAKOVIC B, PAVELIC K: Insulin-like growth factor 2 and its receptors (IGF 1R and IGF 2R/mannose 6-phosphate in endometrial adenocarcinomas. **Gynecol. Oncol.** 105:727-735, 2007. **Q1**
235. GAZIVODA T., RAIĆ-MALIĆ S., KRIŠTAFOR V., MAKUC D., PLAVEC J., BRATULIĆ S., KRALJEVIĆ PAVELIĆ S., PAVELIĆ K., NAESENS L., ANDREI G., SNOECK R., BALZARINI J., MINTAS M.: Synthesis, cytostatic and anti-HIV evaluations of the new unsaturated acyclic C-5 pyrimidine nucleoside analogues. **Bioorganic Med. Chem.**, 16:5624-5634, 2008. **Q1**
236. DŽIMBEG G., ZORC B., KRALJ M., ESTER K., PAVELIĆ K., ANDREI G., SNOECK R., BALZARINI J., DE CLERCQ E., MINTAS M.: The novel primaquine derivatives of N-alkyl, cycloalkyl or aryl urea: Synthesis, cytostatic and antiviral activity evaluations. **Europ. J. Med. Chem.** 43:1180-1187, 2008. **Q1**
237. MALČIĆ A., JUKIĆ S., NAIĆ I., PAVELIĆ B., KAPITANOVIĆ S., KRUŠLIN B., PAVELIĆ K.: Alterations of FHIT and P53 genes in keratocystic odontogenic tumor, dentigerous and radicular cyst. **J. Oral. Pathol. Med.** 37:294-301, 2008. **Q2**
238. HRAŠČAN R., PEĆINA-ŠLAUS N., MARTIĆ T.N., ČOLIĆ J.F., GALL-TROŠELJ K., PAVELIĆ K., KARAPANDŽA N.: Analysis of selected genes in neuroendocrine tumors: insulinomas and phaeochromocytomas. **J. Neuroendocrin.**, 20:1-8, 2008. **Q1**
239. SEDIC M, POZNIC M, GEHRIG P, SCOTT M, SCHLAPBACH R, HRANJEC M, KARMINSKI-ZAMOLA G, PAVELIC K, KRALJEVIC PAVELIC S: Differential antiproliferative mechanisms of novel derivative of benzimidazol /1,2- $\square$ )quinoline in colon cancer cells depending on their p53 status. **Mol. Cancer Ther.** 7:2121-2132, 2008. **Q1**
240. PERKOVIĆ, I., BUTULA I., ZORC B., HOCK K., KRALJEVIĆ PAVELIĆ S., PAVELIĆ K., DE CLERCQ E., BALZARINI J., MINTAS M. Novel lipophilic hydroxyurea derivatives: synthesis, cytostatic and antiviral activity evaluations. **Chem. Biol. Drug. Des.** 71:546-553, 2008. **Q2**
241. BOŠNJAK H., PAVELIC K., KRALJEVIC PAVELIC S.: Towards preventive medicine. High-throughput methods from molecular biology are about to change daily clinical practice. **EMBO Rep.** 9:1056-1060. 2008. **Q1**
242. HRANJEC M, PIANTANIDA I, KRALJ M, ŠUMAN L, PAVELIĆ K, KARMINSKI-ZAMOLA G: Novel amidino-substituted thienyl- and furylvinylbenzimidazole: Derivatives and their

photochemical conversion into corresponding diazacyclopenta(c)fluorenes. Synthesis, interactions with DNA and RNA, and antitumor evaluation 4. **J. Med. Chem.** 51:4899-4910, 2008. **Q1**

243. KRALJEVIĆ PAVELIĆ S, SEDIĆ M, HOCK K, VUČINIĆ S, JURIŠIĆ D, GEHRING P, SCOTT M, SCHLAPBACH R, ČAČEV T, KAPITANOVIĆ S, PAVELIĆ S: An integrated proteomics approach for studying the molecular pathogenesis of Dupuytren's disease. **J. Pathol.** 217:524-533, 2009. **Q1**
244. ESTER K, HRANJEC M, PIANTANIDA I., ĆALETA I, JARAK I, PAVELIĆ K, KRALJ M, KARMINSKI-ZAMOLA G.: Novel derivatives of pyridylbenzol/b thiophene-2-carboxamides and benzo/b/thienol/2,3-c/naphthyridin-2-ones: Minor structural variations provoke major differences of antitumor action mechanisms. **J. Med. Chem.** 52:2482-2492, 2009. **Q1**
245. ĆALETA I, KRALJ M, MARJANOVIĆ M, BERTOŠA B, TOMIĆ S, PAVLOVIĆ G, PAVELIĆ K, KARMINSKI-ZAMOLA G.: Novel cyano- and amidinobenzothiazolo derivatives: synthesis, antitumor evaluation, and X-ray and quantitative structure – Activity relationship (QSAR) analysis. **J. Med. Chem.** 52:1744-1756, 2009. **Q1**
246. RAJIC Z, BUTULA I, ZORC B, KRALJEVIC PAVELIC S, HOCK K, PAVELIC K., DECLERCQ E, BALZARINI JH, PRZYBOROWSKA M, OSSOWSKI T, MINTAS M: Cytostatic and antiviral activity evaluations of hydroxamic derivatives of some non-steroidal anti-inflammatory drugs. **Chem.Biol. Drug. Des.** 73:328-338, 2009. **Q2**
247. RADULESCU RT, POZNIĆ M, PAVELIĆ K. (2009) Complex formation between metabolic enzymes in tumor cells: unfolding the MDR1-IDE paradigm. **Mol. Cancer Ther.** 8:3171-3172, 2009. **Q1**
248. KRALJEVIĆ PAVELIĆ S, BRATULIĆ S, HOCK K, JURIŠIĆ D, HRANJEC M, KARMINSKI-ZAMOLA G, ŽINIĆ B, BUJAK M, PAVELIĆ K: Screening of potential prodrugs on cells derived from Dupuytren's disease patients. **Biomed. Pharmacother.** 63:577-585, 2009. **Q2**
249. SEDIC M, JURISIC D, STANEC Z, HOCK K, PAVELIC K, KRALJEVIC PAVELIC S.: Functional genomics in identification of drug targets in Dupuytren's contracture. **Frontiers Biosci.** 15:57-64, 2010. **Q1**
250. RATKAJ I, ŠTAJDUHAR E, VUČINIĆ S, SPAVENTI Š, BOŠNJAK H, PAVELIĆ K, KRALJEVIĆ PAVELIĆ S. Integrated gene networks in breast cancer development. **Functional & Integrative Genomics**, 15:57-64, 2010. **Q2**
251. BENCI K, WITTINE K, RADAN M, CETINA M, SEDIC M, KRALJEVIC PAVELIC S, PAVELIC K, DE CLERCQ E, MINTAS M: The unsaturated acyclic nucleoside analogues bearing a sterically constrained (Z)-4'-benzamido-2'-butenyl moiety: Synthesis, X-ray crystal structure study, cytostatic and antiviral activity evaluations. **Bioorganic. Med. Chem.** 18:6349-6257, 2010. **Q1**
252. KRALJEVIĆ PAVELIĆ S, SEDIĆ M, POZNIĆ M, RAJIĆ Z, ZORC B, PAVELIĆ K, BALZARINI J, MINTAS M. Evaluation of *in vitro* biological activity of O-alkylated hydroxamic derivatives of some nonsteroidal anti-inflammatory drugs. **Anticancer Res.** 30:3987--3994, 2010. **Q2**
253. RACANE L, TRALIĆ-KULENOVIĆ V, KRALJEVIĆ PAVELIĆ S, RATKAJ I, PEIXOTO P, NHILI R, DEPAUW S, HILDEBRAND M-P, DAVID-CORDONNIER M-H, PAVELIĆ K, KARMINSKI-ZAMOLA G: Novel diamidino-substituted derivatives of phenyl-benzothiazolyl- and dibenzothiazolyl furans and thiophenes: synthesis, antiproliferative and DNA binding properties, **J. Med. Chem.**, 53 : 2418-2432., 2010. **Q1**

254. KOZARIĆ-KOVAČIĆ, D.; PAVELIĆ, K.; FILIPAC, V.; CINDRIĆ, M.; VUČINIĆ, S.; KRALJEVIĆ PAVELIĆ, S., "Proteomics and Posttraumatic Stress Disorder (PTSD)" // Coping with Posttraumatic Stress Disorder in Returning Troops: Wounds of War II / Wiederhold, Brenda, K ; (ur.). Amsterdam, Berlin, Tokio, Washington D.C. : IOS Press, Str. 57-61, 2010.
255. SEDIC M, KRALJEVIC PAVELIC S, CINDRIC M, PERONJA M, WISSENSER H, JOSIC D, CUK M, FUMIC K, BARIC I, PAVELIC K Plasma biomarker identification in S-adenosylhomocysteine hydrolase deficiency. **Electrophoresis**. 32:1970-1975, 2011. **Q1**
256. KOLUNDŽIĆ R, TRKULJA V, MIKOŁAUCIC M, KOLUNDŽIĆ M, PAVELIC KRALJEVIC S, PAVELIC K: Association of interleukin-6 and transforming growth factor- $\beta$ 1 gene polymorphisms with developmental hip dysplasia and severe adult hip osteoarthritis: a preliminary study. **Cytokines**, 54:125-128, 2011. **Q1**
257. KRALJEVIC PAVELIC S, SEDIC M, BOSNJAK H, SPAVENTI S, PAVELIC K: Metastasis: new perspectives on an old problem. **Molecular Cancer**, 10:22-36, 2011. **Q1**
258. WITTINE K, BENCI K, KRALJEVIĆ PAVELIĆ S, PAVELIĆ K, BRATULIĆ S, HOCK K, BALZARINI J, MINTAS M. Synthesis, cytostatic and antiviral activity evaluation of the novel acyclic nucleoside analogues containing a sterically constrained (Z)-4-amino-2-butenyl moiety. **Med. Chem. Res.** 20:280-287, 2011. **Q1**
259. WITTINE K, STIPKOVIĆ BABIĆ M, KOŠUTIĆ M, CETINA M, RIASSEN K, KRALJEVIĆ PAVELIĆ S, TOMLJENOVIC PARAVIĆ A, SEDIĆ M, PAVELIĆ K, MINTAS M.: The new 5- or 6-azapyrimidine and cyanic acid derivatives of L-ascorbic acid bearing the free C-5 hydroxy or C-4 group at the ethylenic spacer: CD-spectral absolute configuration determination and biological activity evaluations. **Europ. J. Med. Chem.** 46:2770-2785, 2011. **Q1**
260. HRANJEC M, STARČEVIĆ K, PAVELIĆ KRALJEVIĆ S, LUČIN P, PAVELIĆ K, KARMINSKI-ZAMOLA G: Synthesis, spectroscopic characterization and antiproliferative evaluation in vitro of novel Shiff bases related to benzimidazoles. **Europ. J. Med. Chem.** 46:2274-2279, 2011. **Q1**
261. BENCI K, SUHINA T, MANDIĆ L, KRALJEVIĆ PAVELIĆ S, TOMLJENOVIC A, PAVELIĆ K, BALZARINI J, WITTINE K, MINTAS M: The novel 1,2,4-triazole and purine acyclic cyclopropane nucleoside analogues: Synthesis, antiviral and cytostatic activity potency evaluations. **Antiviral Chem. Chemother.** 21:221-230, 2011. **Q2**
262. HRANJEC M, LUCIC B, RATKAJ I, KRALJEVIĆ PAVELIC S, PIANTANIDA I, PAVELIC K, KARMINSKI-ZAMOLA G: Novel imidazo[4,5-b]pyridine and triaza-benzo[c]fluorene derivatives: Synthesis, antiproliferative activity and DNA binding studies. **Eur. J. Med. Chem.** 46 : 2748-2758, 2011. **Q1**
263. WITTINE K, STIPKOVIĆ BABIĆ M, MAKUC D, PLAVEC J, KRALJEVIĆ PAVELIĆ S, SEDIĆ M, PAVELIĆ K, LEYSSEN P, NEYTS J, MINTAS M: The Novel 1,2,4-Triazole-3-carboxamide and imidazole derivatives of L-ascorbic acid: Synthesis, anti-HCV and antitumor activity evaluations. **Bioorganic Medicinal Chem.** 20:3675-3685, 2012. **Q1**
264. RACANE L, KRALJEVIĆ PAVELIĆ S, RATKAJ I, STEPANIĆ V, PAVELIĆ K, TRALIĆ-KULENOVIĆ V, KARMINSKI-ZAMOLA G. Synthesis and antiproliferative evaluation of some new amidino-substituted bis-benzothiazolyl-pyridines and pyrazine. **Eur. J. Med. Chem.**, 55:108-116, 2012. **Q1**
265. RATKAJ I, BUJAK M, JURIŠIĆ D, BAUS L, SEDIĆ M, BENDELJA K, PAVELIĆ K, KRALJEVIĆ PAVELIĆ S: Microarray analysis of Dupuytren's disease cells: the profibrogenic role of the TGF- $\beta$  inducible p38 MAPK pathway. **Cell. Physiol. Biochem.**..30:927-942, 2012. **Q2**

266. BENCI K, MANDIĆ L, SUHINA T, SEDIĆ M, KLOBUČAR M, KRALJEVIĆ PAVELIĆ S, PAVELIĆ K, WITTINE K, MINTAS M: Novel Coumarin Derivatives Containing 1,2,4-Triazole, 4,5-Dicyanoimidazole and Purine Moiety: Synthesis and Evaluation of Cytostatic Activity. **Molecules**, 17:11010-11025, 2012. **Q1**
267. MUNJAS JURKIĆ L, KRALJEVIĆ PAVELIĆ S, CEPANEC I, PAVELIĆ K. Zeolites and orthosilicic acid: new perspectives for therapy. **Nutrition & Metabolism**, 10:2 doi:10.1186/1743-7075-10-2, 2013. **Q1**
268. HRANJEC M, SOVIĆ I, RATKAJ I, PAVLOVIĆ G, ILIĆ N, VALJALO L, PAVELIĆ K, KRALJEVIĆ PAVELIĆ S, KARMINSKI-ZAMOLA G: Antiproliferative potency of novel benzofuran-2-carboxamides on tumor cell lines: cell death mechanisms and determination of crystal structure **Eur. J. Med. Chem.** 59:111-119, 2013. **Q1**
269. WITTINE K, POLJAK K, KOVAC M, MAKUC D, PLAVEC J, BALZARINI J, MARTINOVIC T, KRALJEVIĆ PAVELIĆ S, PAVELIĆ K, MINTAS M: The novel 84,5-e)(1,3)diazepine-4,8-dione and acyclic carbamoyl imino-ureido derivatives of imidazole: Synthesis, anti-viral and anti-tumor activity evaluations. **Molecules** 18:13385-13397, 2013. **Q1**
270. ŠABAN N, STEPANIĆ V, VUČINIĆ S, HORVATIĆ A, CINDRIĆ M, PERKOVIĆ I, ZORC B, ORŠOLIĆ N, MINTAS M, PAVELIĆ K, KRALJEVIĆ PAVELIĆ C: Antitumor mechanisms of amino acid hydroxyurea derivatives. **Int. J. Mol. Sci.** 14:23654-23671, 2013. **Q1**
271. RACANE L, KRALJEVIC PAVELIC S, NHILI R, DEPAUW S, CONSTANT C-P, RATKAJ I, DAVID-CORDONNIER M-H, PAVELIC K, TRALIC-KULENOVIC V, KARMINSKI-ZAMOLA G: New anticancer active and selective phenylene-bisbenzothiazoles: Synthesis, Antiproliferative Evaluation and DNA binding. **Eur. J. Med. Chem.**, 63:882-891, 2013. **Q1**
272. ŠTAJDUHAR E, SEDIĆ M, LENIČEK T, RADULOVIĆ P, KERENJI A, KRUŠLIN B, PAVELIĆ K, KRALJEVIĆ PAVELIĆ S: Expression of growth hormone receptor, plakoglobin and NEDD9 protein in association with tumour progression and metastasis in human breast cancer. **Tumor Biol.** 35:6425-6434, 2014. **Q3**
273. KAPITANOVIĆ S, ČAČEV T, LONČAR B, CATELA IVKOVIĆ T, KRIŽANAC Š, PAVELIĆ K: Reduced FHI expression is associated with tumor progression in sporadic colon adenocarcinoma. **Exp. Mol. Path.** 96:92-97, 2014. **Q1**
274. SEDIĆ M, PAVELIĆ K, JOSIĆ D, KRALJEVIĆ PAVELIĆ S Peptidomics to study age-related diseases: spotlight on cancer and neurodegeneration. **Peptidomics** 1:65-76, 2014.
275. IVANIŠEVIĆ MALČIĆ A, BREEN L, JOSIĆ D, JUKIĆ KRMEK S, DŽOMBETA T, MATIJEVIĆ J, GRGUREVIĆ L, PAVELIĆ K, KRUŠLIN B, KRALJEVIĆ PAVELIĆ: Proteomics profiling of keratocystic odontogenic tumours reveals AIDA as novel biomarker candidate. **J Oral Pathol Med.** DOI: 10.1111/jop.12239, 2014. **Q2**
276. ŠALE S, PAVELIĆ K: Mammary Lineage Tracing: The Coming of Age. **J. Cell. Mol. Life Sci.** 72:1577-1583, 2015. **Q1**
277. PAVELIĆ K, MARTINOVIC T, KRALJEVIĆ PAVELIĆ S: Do we understand the personalized medicine paradigm? **EMBO Rep** 16:133-136, 2015. **Q1**
278. MARTINOVIC T, PAVELIĆ K: Stem cells and regenerative medicine: scientific, political and social aspects. **Period biol** 117:5-10, 2015. **Q3**
279. KRALJEVIĆ PAVELIĆ S, KLOBUČAR M, SEDIĆ M, MICEK V, GEHRIG P, GROSSMAN J, PAVELIĆ K, VOJNIKOVIĆ B: UV-induced retinal proteome changes in the rat model of age-related macular degeneration. **BBA - Mol Basis Dis**, 1852:1833-2012, 2015. **Q1**

280. STIPKOVIĆ BABIĆ M, MAKUC D, PLAVEC J, MARTINOVIC T, KRALJEVIĆ PAVELIĆ S, PAVELIĆ K, SNOECK R, ANDREI G, SCHOLS D, WITTINE K, MINTAS M: Novel halogenated 3-deazapurine, 7-deazapurine and alkylated 9-deazapurine derivatives of l-ascorbic or imino-l-ascorbic acid: Synthesis, antitumour and antiviral activity evaluations. **Eur. J. Med. Chem.** 102:288–302, 2015. **Q1**
281. BUJAK M, RATKAJ I, MARKOVA-CAR E, JURIŠIĆ D, HORVATIĆ A, VUČINIĆ S, LERGA J, BAUS-LONČAR M, PAVELIĆ K, KRALJEVIĆ PAVELIĆ S: Inflammatory gene expression upon TGF-β1-Induced p38 activation in primary Dupuytren's disease fibroblasts. **Frontiers Bio. Sci.** 2:1-9, 2015. **Q1**
282. WITTINE K, RATKAJ I, BENCI K, SUHINA T, MANDIĆ L, ILIĆ N, KRALJEVIĆ PAVELIĆ S, PAVELIĆ K, MINTAS M (2016): The novel coumarin (3,2.c)thiophene and its hydroxamic acid and ureido derivatives: synthesis and cytostatic activity evaluations. **Med. Chem. Res.** 25:728-737, 2016. **Q1**
283. KLOBUČAR M, SEDIĆ M, GEHRIG P, GROSSMANN J, BILIĆ M, KOVAČ BILIĆ L, PAVELIĆ K, PAVELIĆ KRALJEVIĆ S (2016): Basement membrane protein lasmin-1 and the MIF-CD 44-β1 integrin signalling axis are implicated in laryngeal cancer metastases. **BBA - Mol Basis Dis,** 1862:1938-1954, **Q1**
284. PAVELIĆ K, SEDIĆ M, KRALJEVIĆ PAVELIĆ S. (2016) Personalized medicine: The path to new medicine. In: Bodiroga-Vukobrat N, Rukavina D, Pavelić K, Sander GG (eds) Personalized medicine: a new medical and social challenge (Europeanization and globalization). Springer International Publishing, New York , 2016.
285. KLOBUČAR M, VISENTIN S, JAKOVČEVIĆ A, BILIĆ M, KOVAČ-BILIĆ L, ĐANIĆ D, PAVELIĆ K, KRALJEVIĆ PAVELIĆ S (2017) Expression of polysialic acid in primary laryngeal squamous cell carcinoma. **Life Sciences,** 173:73-79, 2017. **Q1**
286. KRALJEVIĆ PAVELIĆ S, MICEK V, FILOŠEVIĆ A, GUMBAREVIĆ D, ŽURGA P, BULOG A, ORCT T, YAMAMOTO Y, PREOČANIN T, PLAVEC J, PETER R, PETRAVIĆ M, VIKIĆ-TOPIĆ D, PAVELIĆ K (2017): Novel, oxygenated clinoptilolite material efficiently removes aluminium from aluminium chloride-intoxicated rats *in vivo*. **Micropor Mesopor Mat** doi: 10.1016/j.micromeso.2017.04.062 249:146-156, 2017 **Q1**
287. MARTINOVIC T, ANDJELKOVIĆ U, KLOBUČAR M, ČERNIGOJ U, VIDIĆ J, LUČIĆ M, PAVELIĆ K, JOSIĆ D. (2018) Affinity chromatography on monolithic supports for simultaneous and high-throughput isolation of immunoglobulins from human serum. **Electrophoresis,** 38: 2909-2913 **Q2**
288. PAVELIĆ K, KRALJEVIĆ PAVELIĆ S (2018). Need for a new medicine. In **Science and Religion. Synergy not Scepticism.** Editors: Kurjak A, Chervenak F, McCullough LB, Hasanovic A. Jaypee, New Delhi, London, Panama 185-195.
289. JOSIC D, MARTINOVIC T, PAVELIC K (2018): Glycosylation and metastases. **Electrophoresis,** 40:140-150. **Q2**
290. KRALJEVIĆ PAVELIĆ S, SIMOVIĆ MEDICA J, GUMBAREVIĆ D, FILOŠEVIĆ A, PRŽULJ N, PAVELIĆ K (2018) Critical review on zeolite clinoptilolite safety and medical applications *in vivo*. **Frontiers Pharmacol** 9:1-15. **Q1**
291. PAVELIĆ K, KLOBUČAR M, KUZELJ D, PRŽULJ M, KRALJEVIĆ PAVELIĆ S (2019) Analysis of the signatures of cancer stem cells in malignant tumors using protein interactomes and the STRING database. In **Analysing Network Data in Biology and Medicine: An Interdisciplinary Textbook for Biological, Medical and Computational Scientists.** Ed. Pržulj N Cambridge University Press, pp. 593-620.

292. MARKOVA-CAR E, PAVELIĆ K (2019) Preimplantation genetic diagnosis. In . **In Embryo as a Person and a Patient.** Editors: Kurjak A, Chervenak F, Jaypee, New Delhi, London, Panama 116-120.
293. PAVELIC K, KRALJEVIC PAVELIC S. (2019) Genomic editing, human enhancement and transhumanism: A brief overview. In . **In Embryo as a Person and a Patient.** Editors: Kurjak A, Chervenak F, Jaypee Brothers, New Delhi, London, Panama 131-143.
294. PAVELIC K, MARTINOVIC T, TEKLIĆ E, GORIŠEK REBERŠEK J, KRALJEVIĆ PAVELIĆ S. In **Personalized Medicine in Healthcare System. Legal, Medical and Economic Implications.** (Europeanization and globalization). Editors: Bodiroga-Vukobrat N, Rukavina D, Pavelić K, Sander G.G. Patient-physician relationship in personalized medicine. Springer International Publishing New York 2019.
295. PAVELIĆ K, PERDIJA Ž. KRALJEVIĆ PAVELIĆ S: In **Personalized Medicine in Healthcare System. Legal, Medical and Economic Implications.** (Europeanization and globalization). Editors: Bodiroga-Vukobrat N, Rukavina D, Pavelić K, Sander G.G. Barriers towards new medicine: personalized and integrative medicine concepts. Springer International Publishing New York 2019.
296. JOSIC D, MARTINOVIC T, ČERNOGOJ U, VIDIĆ J, PAVELIC K., In **Personalized Medicine in Healthcare System. Legal, Medical and Economic Implications.** (Europeanization and globalization). Editors: Bodiroga-Vukobrat N, Rukavina D, Pavelić K, Sander G.G. High-throughput analytics in the function of personalized medicine. Springer International Publishing New York 2019.
297. HAREJ A, MEŠČIĆ MACAN A, STEPANIĆ V, KLOBUČAR M, PAVELIĆ K, KRALJEVIĆ PAVELIĆ S, SI RAIĆ-MALIĆ S: (2019). Antioxidant and antiproliferative activities of 1,2,3-triazolyl-L-ascorbic acid derivatives. *Int. J. Mol. Sci.*, 20:4735 doi:10.3390/ijm 2014735 **Q1**
298. MEŠČIĆ MACAN A, HAREJ A, CAZIN I, KLOBUČAR M, STEPANIĆ V, PAVELIĆ K, KRALJEVIĆ PAVELIC S, SCHOLS D, SNOECK R, ANDREI G, RAIĆ-MALIĆ S: (2019) Antitumor and antiviral activities of 4-substituted 1,2,3-triazolyl-2,3-dibenzyl-L-ascorbic acid derivatives. *Eur. J. Med. Chem.* 184: 111739 <https://doi.org/10.1016/j.ejmech.2019.111739>. **Q1**
299. VISENTIN S, SEDIC M, KRALJEVIC PAVELIC S, PAVELIC K. (2020) Targeting tumor metastasis: the emerging role of nanotechnology. *Curr. Med. Chem.* 27:(8) :1367-1381. DOI : 10.2174/092986732666181220095343 **Q1**
300. EISENWAGEN S, PAVELIC K: (2020) Potential role of zeolites in rehabilitation of cancer patients. *Arch. Physiother. Rehab.* 3(1)18-29.
301. REP V., PIŠKOR M, ŠIMEK H, MIŠETIĆ P, GRBČIĆ P, PADOVAN J, GABELICA MARKOVIĆ V, JADREŠKO D, PAVELIĆ K, KRALJEVIĆ PAVELIĆ S, RAIĆ MALIĆ S. (2020) Purine and purine isostere derivatives of ferrocene: An evaluation of ADME, antitumor and electrochemical properties. *Molecules*, 3: doi:10.3390/molecules25071570 **Q1**
302. SAFTIĆ MARTINOVIC L, PERŠURIĆ Ž., PAVELIĆ K. (2020) Nutraceuticals and Metastasis Development. *Molecules*, 25, 2222; doi:10.3390/molecules25092222 **Q1**
303. KRALJEVIĆ PAVELIĆ S, MICEK V, BOBINAC D, BAZDULJ E, GIANONCELLI A, KRPAN D, ŽUVIĆ M, EISENWAGEN S, STAMBROOK JP, PAVELIĆ K.: (2020) Treatment of osteoporosis with a modified zeolite shows beneficial effects in an osteoporotic rat model and a human clinical trial. *Exp. Biol. Med.* 2020; 0: 1–9. DOI: 10.1177/1535370220968752 **Q1**

304. HAO J, LANG S, MANTE F, PAVELIC K, OZER F (2021): The Antimicrobial and Mechanical Effects of Zeolite Use in Dental Materials: A Systematic Review: Zeolite Use in Dental Materials: A Systematic Review. *Acta Stomatol. Croat.* 55 (1): 76-89. DOI: 10.15644/asc55/1/9 **Q3**
305. PAVELIĆ K, KRALJEVIĆ PAVELIĆ S, BRIX B, GOSWAMI N (2021): A perspective on COVID-19 management. *J. Clin. Med.* 10:1586, <https://doi.org/10.3390/jcm10081586> **Q1**
306. BISTROVIĆ POPOV A, VIANELO R, GRBČIĆ P, SEDIĆ M, KRALJEVIĆ PAVELIĆ S, PAVELIĆ K, RAIĆ-MALIĆ S (2021): Novel bis- and mono-pyrolo [2,3-d]pyrimidine and purine derivatives: synthesis, computational analysis and antiproliferative evaluation. *Molecules*, (2021), 26, 3334/doi.org/10.3390/molecules 26113334 **Q1**
307. HAO J, STAVLJENIĆ-MILAŠIN I, EKEN ZB, MRAVAK-STIPETIĆ M, PAVELIĆ K, OZER F (2021): Effects of zeolites as drug delivery system on cancer therapy: A systematic review. *Molecules*, <https://doi.org/10.3390/molecules26206196> **Q1**
308. MARAČIĆ S, GRBČIĆ P, SHAMMUGAM S, RADIĆ STOJKOVIĆ M, PAVELIĆ K, SEDIĆ M, KRALJEVIĆ PAVELIĆ S, RAIĆ-MALIĆ S (2021) Amidine- and amidoxime-substituted heterocycles: synthesis, 2 antiproliferative evaluations and DNA binding. *Molecules* 2021, 26, x. <https://doi.org/10.3390/molecules26227060> **Q1**
309. TRIVANOVIĆ D, PAVELIĆ K, PERŠURIĆ Ž (2021): Fighting cancer with bacteria and their toxins. *Int J Mol Sci*, 22, 1298 <https://doi.org/10.3390/ijms 22231 2980> **Q1**
310. PAVELIĆ K (2021): Personalized neoantigen vaccine against cancer. *Psychiatria Danubina* 2021; Vol. 33, Suppl 3, pp S331-S335, *Science, Art & Religion* 2021, Vol. 1, No 1-2, pp 96-100. <https://www.google.com/search?client=firefox-b-d&q=Psychiatria+Danubina+2021%3B+Vol.+33%2C+Suppl+3%2C+pp+S331-S335+Science%2C+Art+%26+Religion+2021%2C+Vol.+1%2C+No+1-2%2C+pp+96-100>
311. PERŠURIĆ Ž, SAFTIĆ L, PAVELIĆ K (2022): The importance of optimal nutrition in health maintenance. In *Novel Perspectives in Economics of Personalized Medicine and Healthcare Systems*. Romina Pržiklas Družeta, Marinko Škare & Sandra Kraljević Pavelić Eds.. Nova. Medicine & Heakthcare, pp 325-349, New York, 2022. Doi:<https://doi.org/10.52305/IMRM1661>
312. PAVELIĆ K, KRALJEVIĆ PAVELIĆ S (2022): Personalized medicine: Challenges and Look Forward. In *Novel Perspectives in Economics of Personalized Medicine and Healthcare Systems*. Romina Pržiklas Družeta, Marinko Škare & Sandra Kraljević Pavelić Eds. Nova. Medicine & Heakthcare, pp 25-51, New York, 2022. Doi:<https://doi.org/10.52305/IMRM1661>.
313. KRALJEVIĆ PAVELIĆ S, KRPAN D, ŽUVIĆ M, EISENWAGEN S, PAVELIĆ K (2022): Clinical parameters in osteoporosis patients supplemented with PMA-zeolite at the end of 5-year double-blinded clinical trial. *Front. Med.* 9:870962. Doi:10.3389/fmed.2022.870962. **Q1**
314. KRALJEVIĆ PAVELIĆ, SAFTIĆ MARTINOVIĆ L, SIMOVIĆ MEDICA J, ŽUVIĆ M, PERDIJA Ž, KRPAN D, EISENWAGEN S, ORCT T, PAVELIĆ K. (2022) Clinical evaluation of defined zeolite-clinoptilolite supplementation effect on the selected blood parameters of patients. *Front. Med.* 2022, 9, Art # 851782, Doi:10.3389/fmed2022.851782. **Q1**
315. LANG S, HAO J, MANTE F, PAVELIC K, OZER F (2022): The effect of zeolite incorporation in the physical properties of sylver-reinforced glass ionomer cement. *J. Mater. Sci. Mater. Med* 33:38, doi: 10.1007/s10856-022-06659-2
316. TRIVANOVIĆ D, PERŠURIĆ Ž, AGAJ A, JAKOPOVIĆ M, SAMARŽIJA M, BITAR L, PAVELIĆ K (2022): The interplay of lung cancer, COVID 19 and vaccines. *Int. J. Mol. Sci.* 23:15067, <https://doi.org/10.3390/ijms232315067>. **Q1**

317. KRALJEVIĆ PAVELIĆ S, PAVELIĆ K, (2022): Open questions over the COVID-19 pandemic. *Sci. Arts Relig.* 105005/jp journals-11005-0027.
318. MARKOSKA R, STOJKOVIĆ R, FILIPOVIĆ M, JURIN M, ŠPADA V, KAVRE PILTAVER I, PAVELIĆ K, MARKOVIĆ D, KRALJEVIĆ PAVELIĆ S (2023): Study of zeolite clinoptilolite D-glucose adsorption properties *in vitro* and *in vivo*. *Chem. Biol. Interact.* 382 (2023) 110641 **Q1**
319. PAVELIĆ K, PAVELIĆ KRALJEVIĆ S, BULOG A, AGAJ A, ROJNIĆ B, ČOLIĆ M, TRIVANOVIC D (2023): Nanoparticles in Medicine: Current Status in Cancer Treatment. *Int. J. Mol. Sci.* 24: ,12827, <https://doi.org/10.3390/ijms241612827> **Q1**
320. ČOLIĆ M, KRALJEVIĆ PAVELIĆ S, PERŠURIĆ Ž, AGAJ A, BULOG A, PAVELIĆ K: Enhancing the bioavailability and activity of natural antioxidants with nanobubbles and nanoparticles. (2024) *Redox Report* 29:1, 2333619, 1-16, 2024. <https://doi.org/10.1080/13510002.2024.2333619> **Q2**
321. TAN J, HAO J, VANN D, PAVELIC K, OZER F (2024): Effect of zeolite incorporation on the ion release properties of silver-reinforced glass ionomer cement. *Biomimetics*, 9, 365. <https://doi.org/10.3390/biomimetics9060365> **Q2**
322. HAO J, CHEN C, PAVELIC K, OZER F (2024): ZIF-8 as a pH-Responsive Nanoplatform for 5-Fluorouracil: Delivery in the Chemotherapy of Oral Squamous Cell Carcinoma *Int. J. Mol. Sci.*, 25(17), 9292; <https://doi.org/10.3390/ijms25179292> **Q1**
323. BULOG A, PAVELIĆ K, ŠUTIĆ I, KRALJEVIĆ PAVELIĆ S: (2024) PMA-Zeolite: chemistry and diverse medical application. *J. Funct. Biomater.*, 15, 296, <https://doi.org/10.3390/jfb15100296> **Q2**
324. TURČIĆ M, KRALJEVIĆ PAVELIĆ S, TRIVANOVIC D, PAVELIĆ K (2024) Interaction of HERVs with PAMPs in Dysregulation of Immune Response Cascade Upon SARS-CoV-2 Infections. *Int. J. Mol. Sci.*, <https://doi.org/10.3390/ijms252413360> **Q1**
325. PIŠKOR M, MILIĆ A, KOŠTRUN S, MAJERIĆ ELENKOV M, GRBČIĆ P, KRALEVIĆ PAVELIĆ S, PAELIĆ K, RAIĆ-MALIĆ S (2025): Synthesis, Antiproliferative Activity, and ADME Profiling of Novel Racemic and Optically Pure Aryl-Substituted Purines and Purine Bioisosteres. *Biomolecules* 2025, 15, 351 (<https://creativecommons.org/licenses/by/4.0/>). **Q1**